Cover
Cover - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 16, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 000-19731 | ||
Entity Registrant Name | GILEAD SCIENCES, INC. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 94-3047598 | ||
Entity Address, Address Line One | 333 Lakeside Drive | ||
Entity Address, City or Town | Foster City | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 94404 | ||
City Area Code | 650 | ||
Local Phone Number | 574-3000 | ||
Title of 12(b) Security | Common Stock, par value, $0.001 per share | ||
Trading Symbol | GILD | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 67 | ||
Entity Common Stock, Shares Outstanding | 1,245,774,616 | ||
Documents Incorporated by Reference | Specified portions of the registrant’s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant’s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Report. | ||
Entity Central Index Key | 0000882095 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Audit Information [Abstract] | |
Auditor Name | Ernst & Young LLP |
Auditor Location | San Mateo, California |
Auditor Firm ID | 42 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 6,085 | $ 5,412 |
Short-term marketable debt securities | 1,179 | 973 |
Accounts receivable, net | 4,660 | 4,777 |
Inventories | 1,787 | 1,507 |
Prepaid and other current assets | 2,374 | 1,774 |
Total current assets | 16,085 | 14,443 |
Property, plant and equipment, net | 5,317 | 5,475 |
Long-term marketable debt securities | 1,163 | 1,245 |
Intangible assets, net | 26,454 | 28,894 |
Goodwill | 8,314 | 8,314 |
Other long-term assets | 4,792 | 4,800 |
Total assets | 62,125 | 63,171 |
Current liabilities: | ||
Accounts payable | 550 | 905 |
Accrued rebates | 3,802 | 3,479 |
Other current liabilities | 5,130 | 4,580 |
Current portion of long-term debt and other obligations, net | 1,798 | 2,273 |
Total current liabilities | 11,280 | 11,237 |
Long-term debt, net | 23,189 | 22,957 |
Long-term income taxes payable | 2,039 | 3,916 |
Deferred tax liability | 1,588 | 2,673 |
Other long-term obligations | 1,280 | 1,179 |
Commitments and contingencies (Note 13) | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
Common stock, par value $0.001 per share; 5,600 authorized; 1,246 and 1,247 shares issued and outstanding, respectively | 1 | 1 |
Additional paid-in capital | 6,500 | 5,550 |
Accumulated other comprehensive income | 28 | 2 |
Retained earnings | 16,304 | 15,687 |
Total Gilead stockholders’ equity | 22,833 | 21,240 |
Noncontrolling interest | (84) | (31) |
Total stockholders’ equity | 22,749 | 21,209 |
Total liabilities and stockholders’ equity | $ 62,125 | $ 63,171 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Stockholders’ equity: | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, authorized (in shares) | 5 | 5 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 5,600 | 5,600 |
Common stock, issued (in shares) | 1,246 | 1,247 |
Common stock, outstanding (in shares) | 1,246 | 1,247 |
CONSOLIDATED STATEMENTS OF INCO
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Total revenues | $ 27,116 | $ 27,281 | $ 27,305 |
Costs and expenses: | |||
Cost of goods sold | 6,498 | 5,657 | 6,601 |
Research and development expenses | 5,718 | 4,977 | 4,601 |
Acquired in-process research and development expenses | 1,155 | 944 | 939 |
In-process research and development impairments | 50 | 2,700 | 0 |
Selling, general and administrative expenses | 6,090 | 5,673 | 5,246 |
Total costs and expenses | 19,511 | 19,951 | 17,387 |
Operating income | 7,605 | 7,330 | 9,918 |
Interest expense | (944) | (935) | (1,001) |
Other income (expense), net | 198 | (581) | (639) |
Income before income taxes | 6,859 | 5,814 | 8,278 |
Income tax expense | (1,247) | (1,248) | (2,077) |
Net income | 5,613 | 4,566 | 6,201 |
Net loss attributable to noncontrolling interest | 52 | 26 | 24 |
Net income attributable to Gilead | $ 5,665 | $ 4,592 | $ 6,225 |
Basic earnings per share attributable to Gilead (in dollars per share) | $ 4.54 | $ 3.66 | $ 4.96 |
Shares used in basic earnings per share attributable to Gilead calculation (in shares) | 1,248 | 1,255 | 1,256 |
Diluted earnings per share attributable to Gilead (in dollars per share) | $ 4.50 | $ 3.64 | $ 4.93 |
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) | 1,258 | 1,262 | 1,262 |
Product sales | |||
Revenues: | |||
Total revenues | $ 26,934 | $ 26,982 | $ 27,008 |
Royalty, contract and other revenues | |||
Revenues: | |||
Total revenues | $ 182 | $ 299 | $ 297 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | |||
Net income: | $ 5,613 | $ 4,566 | $ 6,201 |
Other comprehensive income (loss), net: | |||
Net foreign currency translation gain (loss) | 60 | (11) | (38) |
Available-for-sale debt securities: | |||
Net unrealized gain (loss), net of tax impact of $0, $0 and $(1), respectively | 26 | (30) | (6) |
Reclassifications to net income, net of tax impact of $0, $0 and $0, respectively | 2 | 1 | 0 |
Net change | 28 | (29) | (6) |
Cash flow hedges: | |||
Net unrealized (loss) gain, net of tax impact of $(2), $20 and $18, respectively | (12) | 130 | 129 |
Reclassifications to net income, net of tax impact of $7, $25 and $(9), respectively | (51) | (171) | 58 |
Net change | (62) | (41) | 187 |
Other comprehensive income (loss), net | 26 | (81) | 143 |
Comprehensive income, net | 5,639 | 4,485 | 6,344 |
Comprehensive loss attributable to noncontrolling interest, net | 52 | 26 | 24 |
Comprehensive income attributable to Gilead, net | $ 5,691 | $ 4,511 | $ 6,368 |
CONSOLIDATED STATEMENTS OF CO_2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Available-for-sale debt securities: | |||
Tax impact of net unrealized gain (loss) | $ 0 | $ 0 | $ (1) |
Tax impact of reclassifications to net income | 0 | 0 | 0 |
Cash flow hedges: | |||
Tax impact of net unrealized (loss) gain | (2) | 20 | 18 |
Tax impact of reclassifications to net income | $ 7 | $ 25 | $ (9) |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Retained Earnings | Noncontrolling Interest |
Beginning balance (in shares) at Dec. 31, 2020 | 1,254 | |||||
Beginning balance at Dec. 31, 2020 | $ 18,221 | $ 1 | $ 3,880 | $ (60) | $ 14,381 | $ 19 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income (loss) | 6,201 | 6,225 | (24) | |||
Other comprehensive income (loss), net | 143 | 143 | ||||
Issuances under employee stock purchase plan (in shares) | 2 | |||||
Issuances under employee stock purchase plan | 111 | 111 | ||||
Issuance under equity incentive plans (in shares) | 9 | |||||
Issuances under equity incentive plans | 58 | 58 | ||||
Stock-based compensation | 640 | 640 | ||||
Repurchases of common stock under repurchase programs (in shares) | (8) | |||||
Repurchases of common stock under repurchase programs | (546) | (28) | (518) | |||
Repurchases of common stock for employee tax withholding under equity incentive plans and other (in shares) | (3) | |||||
Repurchases of common stock for employee tax withholding under equity incentive plans and other | (146) | (146) | ||||
Dividends declared | (3,618) | (3,618) | ||||
Ending balance (in shares) at Dec. 31, 2021 | 1,254 | |||||
Ending balance at Dec. 31, 2021 | 21,064 | $ 1 | 4,661 | 83 | 16,324 | (5) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income (loss) | 4,566 | 4,592 | (26) | |||
Other comprehensive income (loss), net | (81) | (81) | ||||
Issuances under employee stock purchase plan (in shares) | 2 | |||||
Issuances under employee stock purchase plan | 103 | 103 | ||||
Issuance under equity incentive plans (in shares) | 13 | |||||
Issuances under equity incentive plans | 211 | 211 | ||||
Stock-based compensation | 640 | 640 | ||||
Repurchases of common stock under repurchase programs (in shares) | (19) | |||||
Repurchases of common stock under repurchase programs | (1,396) | (65) | (1,331) | |||
Repurchases of common stock for employee tax withholding under equity incentive plans and other (in shares) | (3) | |||||
Repurchases of common stock for employee tax withholding under equity incentive plans and other | (173) | (173) | ||||
Dividends declared | $ (3,725) | (3,725) | ||||
Ending balance (in shares) at Dec. 31, 2022 | 1,247 | 1,247 | ||||
Ending balance at Dec. 31, 2022 | $ 21,209 | $ 1 | 5,550 | 2 | 15,687 | (31) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income (loss) | 5,613 | 5,665 | (52) | |||
Other comprehensive income (loss), net | 26 | 26 | ||||
Issuances under employee stock purchase plan (in shares) | 2 | |||||
Issuances under employee stock purchase plan | 129 | 129 | ||||
Issuance under equity incentive plans (in shares) | 13 | |||||
Issuances under equity incentive plans | 99 | 99 | ||||
Stock-based compensation | 767 | 767 | ||||
Repurchases of common stock under repurchase programs (in shares) | (13) | |||||
Repurchases of common stock under repurchase programs | (1,000) | (45) | (955) | |||
Repurchases of common stock for employee tax withholding under equity incentive plans and other (in shares) | (4) | |||||
Repurchases of common stock for employee tax withholding under equity incentive plans and other | (279) | (279) | ||||
Dividends declared | $ (3,814) | (3,814) | ||||
Ending balance (in shares) at Dec. 31, 2023 | 1,246 | 1,246 | ||||
Ending balance at Dec. 31, 2023 | $ 22,749 | $ 1 | $ 6,500 | $ 28 | $ 16,304 | $ (84) |
CONSOLIDATED STATEMENTS OF ST_2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) - $ / shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Statement of Stockholders' Equity [Abstract] | |||
Average price per share (in dollars per share) | $ 79.52 | $ 73.77 | $ 66.58 |
Dividends declared (in dollars per share) | $ 3 | $ 2.92 | $ 2.84 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Activities: | |||
Net income: | $ 5,613 | $ 4,566 | $ 6,201 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation expense | 354 | 323 | 329 |
Amortization expense | 2,339 | 1,780 | 1,721 |
Stock-based compensation expense | 766 | 637 | 635 |
Deferred income taxes | (962) | (1,552) | (116) |
Net loss from equity securities | 167 | 657 | 610 |
Acquired in-process research and development expenses | 1,155 | 944 | 939 |
In-process research and development impairments | 50 | 2,700 | 0 |
Other | 826 | 780 | 576 |
Changes in operating assets and liabilities: | |||
Accounts receivable, net | 157 | (406) | 313 |
Inventories | (842) | (310) | 11 |
Prepaid expenses and other | 39 | (134) | (45) |
Accounts payable | (347) | 226 | (118) |
Income tax assets and liabilities, net | (1,768) | (364) | (361) |
Accrued and other liabilities | 458 | (775) | 689 |
Net cash provided by operating activities | 8,006 | 9,072 | 11,384 |
Investing Activities: | |||
Purchases of marketable debt securities | (1,930) | (1,770) | (3,517) |
Proceeds from sales of marketable debt securities | 510 | 412 | 730 |
Proceeds from maturities of marketable debt securities | 1,334 | 1,590 | 2,180 |
Acquisitions, including in-process research and development, net of cash acquired | (1,152) | (1,797) | (1,584) |
Purchases of equity securities | (442) | (172) | (380) |
Capital expenditures | (585) | (728) | (579) |
Other | (1) | (1) | 19 |
Net cash used in investing activities | (2,265) | (2,466) | (3,131) |
Financing Activities: | |||
Proceeds from debt financing, net of issuance costs | 1,980 | 0 | 0 |
Proceeds from issuances of common stock | 232 | 309 | 169 |
Repurchases of common stock under repurchase programs | (1,000) | (1,396) | (546) |
Repayments of debt and other obligations | (2,250) | (1,500) | (4,750) |
Payments of dividends | (3,809) | (3,709) | (3,605) |
Other | (279) | (173) | (145) |
Net cash used in financing activities | (5,125) | (6,469) | (8,877) |
Effect of exchange rate changes on cash and cash equivalents | 57 | (63) | (35) |
Net change in cash and cash equivalents | 673 | 74 | (659) |
Cash and cash equivalents at beginning of period | 5,412 | 5,338 | 5,997 |
Cash and cash equivalents at end of period | 6,085 | 5,412 | 5,338 |
Supplemental disclosure of cash flow information: | |||
Interest paid, net of amounts capitalized | 891 | 907 | 979 |
Income taxes paid | $ 3,990 | $ 3,136 | $ 2,509 |
ORGANIZATION AND SUMMARY OF SIG
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, coronavirus disease 2019 (“COVID-19”) and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our portfolio of marketed products includes AmBisome ® , Atripla ® , Biktarvy ® , Cayston ® , Complera ® , Descovy ® , Descovy for PrEP ® , Emtriva ® , Epclusa ® , Eviplera ® , Genvoya ® , Harvoni ® , Hepcludex ® , Hepsera ® , Jyseleca ® , Letairis ® , Odefsey ® , Sovaldi ® , Stribild ® , Sunlenca ® , Tecartus ® , Trodelvy ® , Truvada ® , Truvada for PrEP ® , Tybost ® , Veklury ® , Vemlidy ® , Viread ® , Vosevi ® , Yescarta ® and Zydelig ® . The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the U.S. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the U.S. through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region. We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (“CODM”), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (“R&D”) projects based on unmet medical need, scientific data, probability of technical and regulatory successful development, market potential and other considerations, and, as necessary, reallocate resources among our internal R&D portfolio and external opportunities to best support the long-term growth of our business. Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and any variable interest entities (“VIEs”) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For any consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the attributable economic or ownership interest retained in such entities by the respective noncontrolling parties. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine them with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $204 million and $3 million from Prepaid expenses and other for the years ended December 31, 2022 and 2021, respectively. Certain amounts and percentages herein may not sum or recalculate due to rounding. Revenue Recognition Product Sales We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, patient co-pay assistance, prompt pay discounts, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation. Gross-to-Net Deductions Rebates and Chargebacks Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us. Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information. Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets. Patient Co-Pay Assistance Co-pay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. Our accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end. Cash Discounts We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. Distributor Fees Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales. Allowance for Sales Returns Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis. Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. Royalty, Contract and Other Revenues Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied. Research and Development Expenses Research and development expenses are recorded when incurred and consist primarily of personnel costs including salaries, benefits and stock-based compensation expense, infrastructure, materials and supplies and other support costs, research and clinical studies performed by contract research organizations (“CROs”) and our collaboration partners and other outside services. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses. Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided. Acquired In-Process Research and Development Expenses Acquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed in-process research and development (“IPR&D”) projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&D projects. Selling, General and Administrative Expenses Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, and sales, marketing and advertising expenses, as well as other general and administrative costs related to finance, human resources, legal and other administrative activities. Advertising expenses within Selling, general and administrative expenses, including promotional expenses, are recorded when incurred and were $826 million, $778 million and $735 million for the years ended December 31, 2023, 2022 and 2021, respectively. Stock-Based Compensation We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (“RSUs”), performance share units (“PSUs”) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the “ESPP”). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability. The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments. Earnings Per Share Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method. Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three months or less on the purchase date to be cash equivalents. Marketable Debt Securities All of our marketable debt securities are classified as available-for-sale and recorded at estimated fair values. We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. Unrealized gains and losses on available-for-sale debt securities are reported in Accumulated other comprehensive income on our Consolidated Balance Sheets until realized, at which point they are reclassified into Other income (expense), net on our Consolidated Statements of Income. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in Accumulated other comprehensive income. Interest and amortization of purchase premiums and discounts are also recorded in Other income (expense), net on our Consolidated Statements of Income. The cost of securities sold is based on the specific identification method. Accounts Receivable Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and estimated credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. Inventories Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. Equity Securities Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income. For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: Description Estimated Useful Life Buildings and improvements Shorter of 35 years or useful life Laboratory and manufacturing equipment 4-10 Office, computer equipment and other 3-15 Leasehold improvements Shorter of useful life or lease term See “Impairment of Long-Lived Assets” for additional information. Leases We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term. We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less. As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See “Impairment of Long-Lived Assets” for additional information. In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset’s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors. In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use. Impairment of Long-Lived Assets Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset over its useful life to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Derivatives We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income. Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income. Contingencies We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. Income Taxes Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (“UTB”) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred. Stock Repurchases We use the par value method of accounting for our stock repurchases made under repurchase programs. Under the par value method, we record the par value of the shares repurchased to Common stock and the historical issuance cost over par value of the shares repurchased to Additional paid-in capital. The excess of the cost of the shares repurchased over these two amounts is then recorded to Retained earnings . Foreign Currency Translation and Transactions Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income. Fair Value Measurements We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks. We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: • Level 1 inputs include quoted prices in active markets for identical assets or liabilities |
REVENUES
REVENUES | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
REVENUES | REVENUES Disaggregation of Revenues The following table summarizes our Total revenues: Year Ended December 31, 2023 Year Ended December 31, 2022 Year Ended December 31, 2021 (in millions) U.S. Europe Other Total U.S. Europe Other Total U.S. Europe Other Total Product sales: HIV Biktarvy $ 9,692 $ 1,253 $ 905 $ 11,850 $ 8,510 $ 1,103 $ 777 $ 10,390 $ 7,049 $ 969 $ 606 $ 8,624 Complera/Eviplera 47 70 12 129 74 113 13 200 102 142 14 258 Descovy 1,771 100 114 1,985 1,631 118 123 1,872 1,397 164 139 1,700 Genvoya 1,752 205 103 2,060 1,983 284 136 2,404 2,267 391 221 2,879 Odefsey 1,012 294 44 1,350 1,058 364 47 1,469 1,076 440 52 1,568 Stribild 72 21 8 101 88 29 10 127 132 43 14 189 Truvada 82 13 19 114 113 15 18 147 314 22 35 371 Revenue share - Symtuza (1) 382 133 13 529 348 168 14 530 355 165 11 531 Other HIV (2) 37 12 7 56 15 24 17 57 136 30 29 195 Total HIV 14,848 2,102 1,226 18,175 13,820 2,219 1,155 17,194 12,828 2,366 1,121 16,315 Oncology Cell Therapy Tecartus 245 110 15 370 221 75 3 299 136 40 — 176 Yescarta 811 547 140 1,498 747 355 57 1,160 406 253 36 695 Total Cell Therapy 1,055 658 156 1,869 968 430 60 1,459 542 293 36 871 Trodelvy 777 217 68 1,063 525 143 12 680 370 10 — 380 Total Oncology 1,833 875 224 2,932 1,494 573 73 2,139 912 303 36 1,251 Liver Disease Chronic hepatitis C virus (“HCV”) Ledipasvir/ Sofosbuvir (3) 39 12 19 70 46 17 51 115 84 31 97 212 Sofosbuvir/Velpatasvir (4) 859 323 355 1,537 844 355 331 1,530 815 316 331 1,462 Other HCV (5) 104 43 12 160 115 40 10 166 119 74 14 207 Total HCV 1,002 378 386 1,767 1,005 413 392 1,810 1,018 421 442 1,881 Chronic hepatitis B virus (“HBV”) / Chronic hepatitis delta virus (“HDV”) Vemlidy 410 38 414 862 429 35 379 842 384 34 396 814 Viread 8 22 52 83 6 23 62 91 11 28 72 111 Other HBV/HDV (6) — 72 — 72 — 55 — 55 2 42 — 44 Total HBV/HDV 418 133 466 1,017 435 112 441 988 397 104 468 969 Total Liver Disease 1,421 511 852 2,784 1,440 525 833 2,798 1,415 525 910 2,850 Veklury 972 408 805 2,184 1,575 702 1,628 3,905 3,640 1,095 830 5,565 Other AmBisome 43 260 189 492 57 258 182 497 39 274 227 540 Letairis 142 — — 142 196 — — 196 206 — — 206 Other (7) 118 40 66 225 135 65 53 253 136 115 30 281 Total Other 304 301 255 859 388 323 235 946 381 389 257 1,027 Total product sales 19,377 4,197 3,361 26,934 18,716 4,342 3,924 26,982 19,176 4,678 3,154 27,008 Royalty, contract and other revenues 62 114 7 182 168 127 4 299 91 196 10 297 Total revenues $ 19,438 $ 4,310 $ 3,368 $ 27,116 $ 18,884 $ 4,469 $ 3,928 $ 27,281 $ 19,267 $ 4,874 $ 3,164 $ 27,305 _______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 7. Collaborations and Other Arrangements for additional information. (2) Includes Atripla, Emtriva, Sunlenca and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig. Revenues from Major Customers The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues: Year Ended December 31, (as a percentage of total revenues) 2023 2022 2021 Cardinal Health, Inc. 26 % 25 % 22 % Cencora, Inc. (formerly known as AmerisourceBergen Corporation) 19 % 18 % 23 % McKesson Corporation 21 % 20 % 20 % Revenues Recognized from Performance Obligations Satisfied in Prior Years The following table summarizes revenues recognized from performance obligations satisfied in prior years: Year Ended December 31, (in millions) 2023 2022 2021 Revenue share with Janssen (1) and royalties for licenses of intellectual property $ 680 $ 783 $ 851 Changes in estimates $ 340 $ 582 $ 856 ________________________________ (1) See Note 7. Collaborations and Other Arrangements for additional information. Contract Balances The following table summarizes our contract balances: December 31, (in millions) 2023 2022 Contract assets (1) $ 117 $ 171 Contract liabilities (2) $ 109 $ 102 ________________________________ (1) Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation. (2) Generally results from receipt of advance payment before our performance under the contract. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: December 31, 2023 December 31, 2022 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Available-for-sale debt securities: U.S. treasury securities $ 426 $ — $ — $ 426 $ 410 $ — $ — $ 410 U.S. government agencies securities — 127 — 127 — 35 — 35 Non-U.S. government securities — 10 — 10 — 34 — 34 Certificates of deposit — 45 — 45 — 54 — 54 Corporate debt securities — 1,451 — 1,451 — 1,427 — 1,427 Residential mortgage and asset-backed securities — 367 — 367 — 333 — 333 Equity securities: Money market funds 4,465 — — 4,465 3,831 — — 3,831 Publicly traded equity securities (1) 1,458 — — 1,458 1,197 — — 1,197 Deferred compensation plan 284 — — 284 220 — — 220 Foreign currency derivative contracts — 7 — 7 — 60 — 60 Total $ 6,633 $ 2,007 $ — $ 8,639 $ 5,658 $ 1,943 $ — $ 7,600 Liabilities: Liability for MYR GmbH (“MYR”) contingent consideration $ — $ — $ 228 $ 228 $ — $ — $ 275 $ 275 Deferred compensation plan 283 — — 283 220 — — 220 Foreign currency derivative contracts — 59 — 59 — 42 — 42 Total $ 283 $ 59 $ 228 $ 570 $ 220 $ 42 $ 275 $ 538 _______________________________ (1) Publicly traded equity securities include investments in Galapagos NV (“Galapagos”) of $686 million and Arcellx, Inc. (“Arcellx”) of $373 million as of December 31, 2023, which are subject to contractual sale restrictions until August 2024 and June 2025, respectively. See Note 7. Collaborations and Other Arrangements for additional information. Level 2 Inputs Available-for-Sale Debt Securities For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. Foreign Currency Derivative Contracts Our foreign currency derivative contracts have maturities of 18 months or less and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P Global Ratings, Moody’s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by utilizing an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (“SOFR”) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals. Senior Unsecured Notes The following table summarizes the total estimated fair value and carrying value of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values: December 31, (in millions) 2023 2022 Fair value $ 22,567 $ 21,872 Carrying value $ 23,834 $ 24,088 Level 3 Inputs Contingent Consideration Liability In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to €300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (“FDA”) approval of Hepcludex until the related contingency is resolved. The following table summarizes the change in fair value of our contingent consideration liability: Year Ended December 31, (in millions) 2023 2022 Beginning balance $ 275 $ 317 Changes in valuation assumptions (1) (60) (21) Effect of foreign exchange remeasurement (2) 12 (21) Ending balance (3) $ 228 $ 275 ________________________________ (1) Included in Research and development expenses on our Consolidated Statements of Income. The changes primarily related to changes in assumptions around probability and timing of regulatory approval. (2) Included in Other income (expense), net on our Consolidated Statements of Income. (3) Included in Other long-term obligations on our Consolidated Balance Sheets as of December 31, 2023 and 2022, respectively. Liability Related to Future Royalties We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (“Immunomedics”), which is subsequently amortized using the effective interest method over the remaining estimated life. See Note 11. Debt and Credit Facilities for additional information. The following table summarizes the fair value and carrying value of the liability related to future royalties: December 31, (in millions) 2023 2022 Fair value $ 1,230 $ 1,090 Carrying value $ 1,153 $ 1,141 Nonrecurring Fair Value Measurements In 2023, we recorded a $51 million write-off of our finite-lived intangible asset related to filgotinib as discussed in Note 9. Goodwill and Intangible Assets, as well as a $381 million write-off of manufacturing assets related to changes in our manufacturing strategy as discussed in Note 10. Other Financial Information. Both charges were recorded within Cost of goods sold on our Consolidated Statements of Income. In 2023 and 2022, we recorded a partial impairment charge of $50 million and $2.7 billion, respectively, related to certain IPR&D assets as discussed in Note 9. Goodwill and Intangible Assets. Fair Value Level Transfers There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. |
AVAILABLE-FOR-SALE DEBT SECURIT
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES | 12 Months Ended |
Dec. 31, 2023 | |
Debt Securities, Available-for-Sale [Abstract] | |
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES | AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES Available-for-Sale Debt Securities The following table summarizes our available-for-sale debt securities: December 31, 2023 December 31, 2022 (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 427 $ — $ (1) $ 426 $ 415 $ — $ (5) $ 410 U.S. government agencies securities 127 — — 127 36 — — 35 Non-U.S. government securities 10 — — 10 34 — — 34 Certificates of deposit 45 — — 45 54 — — 54 Corporate debt securities 1,455 4 (8) 1,451 1,452 — (26) 1,427 Residential mortgage and asset-backed securities 366 1 — 367 335 — (3) 333 Total $ 2,430 $ 5 $ (10) $ 2,426 $ 2,325 $ 1 $ (34) $ 2,293 The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time: December 31, 2023 Less Than 12 Months 12 Months or Longer Total (in millions) Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ — $ 161 $ (1) $ 48 $ (1) $ 209 U.S. government agencies securities — 106 — 2 — 108 Non-U.S. government securities — 5 — 5 — 10 Corporate debt securities (1) 333 (7) 546 (8) 878 Residential mortgage and asset-backed securities — 123 — 24 — 147 Total $ (2) $ 727 $ (8) $ 624 $ (10) $ 1,351 December 31, 2022 Less Than 12 Months 12 Months or Longer Total (in millions) Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ (2) $ 174 $ (3) $ 206 $ (5) $ 379 U.S. government agencies securities — 21 — — — 21 Non-U.S. government securities — 31 — 3 — 34 Corporate debt securities (17) 774 (8) 439 (26) 1,213 Residential mortgage and asset-backed securities (2) 205 (1) 56 (3) 261 Total $ (22) $ 1,204 $ (12) $ 705 $ (34) $ 1,908 No allowance for credit losses was recognized for investments with unrealized losses as of December 31, 2023, as the unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments. We do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases. The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: December 31, (in millions) 2023 2022 Cash and cash equivalents $ 83 $ 75 Short-term marketable debt securities 1,179 973 Long-term marketable debt securities 1,163 1,245 Total $ 2,426 $ 2,293 The following table summarizes our available-for-sale debt securities by contractual maturity: December 31, 2023 (in millions) Amortized Cost Fair Value Within one year $ 1,267 $ 1,262 After one year through five years 1,153 1,153 After five years through ten years 9 9 After ten years 2 2 Total $ 2,430 $ 2,426 Equity Securities The following table summarizes the classification of our equity securities on our Consolidated Balance Sheets: December 31, (in millions) 2023 2022 Equity securities measured at fair value: Cash and cash equivalents $ 4,465 $ 3,831 Prepaid and other current assets 1,086 473 Other long-term assets 656 943 Equity method investments and other equity investments without readily determinable fair values: Other long-term assets $ 340 $ 423 Total $ 6,547 $ 5,671 For our equity method investments in Galapagos and Arcus Biosciences, Inc. (“Arcus”), we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is subject to certain lock-up provisions until August 2024 and was classified in Prepaid and other current assets and Other long-term assets as of December 31, 2023 and 2022 at $686 million and $736 million, respectively. Our investment in Arcus was classified in Prepaid and other current assets as of December 31, 2023 and 2022 at $283 million and $286 million, respectively. Unrealized Gains and Losses The following table summarizes net unrealized gains and losses on equity securities still held as of the respective balance sheet dates, included in Other income (expense), net on our Consolidated Statements of Income: Year Ended December 31, (in millions) 2023 2022 2021 Net unrealized losses on equity securities still held $ 60 $ 684 $ 647 Related Party Transaction During the years ended December 31, 2022 and 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (the “Foundation”). The Foundation is a related party as certain of our officers also serve as directors of the Foundation. The donation expense of $85 million and $212 million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income during the years ended December 31, 2022 and 2021, respectively. |
DERIVATIVE FINANCIAL INSTRUMENT
DERIVATIVE FINANCIAL INSTRUMENTS | 12 Months Ended |
Dec. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
DERIVATIVE FINANCIAL INSTRUMENTS | DERIVATIVE FINANCIAL INSTRUMENTS Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. We held foreign currency exchange contracts with outstanding notional amounts of $2.5 billion and $3.0 billion as of December 31, 2023 and 2022, respectively. While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: December 31, 2023 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 6 Other current liabilities $ 38 Foreign currency exchange contracts Other long-term assets — Other long-term obligations 7 Total derivatives designated as hedges 6 45 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 15 Total derivatives not designated as hedges 1 15 Total derivatives presented gross on the Consolidated Balance Sheets $ 7 $ 59 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments $ (7) $ (7) Cash collateral received / pledged — — Net amount (legal offset) $ — $ 52 December 31, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 59 Other current liabilities $ 26 Foreign currency exchange contracts Other long-term assets 1 Other long-term obligations 9 Total derivatives designated as hedges 59 35 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 7 Total derivatives not designated as hedges 1 7 Total derivatives presented gross on the Consolidated Balance Sheets $ 60 $ 42 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments $ (36) $ (36) Cash collateral received / pledged — — Net amount (legal offset) $ 25 $ 7 The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements: Year Ended December 31, (in millions) 2023 2022 2021 Derivatives designated as hedges: Net (loss) gain recognized in Accumulated other comprehensive income (loss) $ (14) $ 150 $ 147 Net gain (loss) reclassified from Accumulated other comprehensive income (loss) into Product sales $ 58 $ 196 $ (67) Derivatives not designated as hedges: Net gain recognized in Other income (expense), net $ 57 $ 67 $ 21 The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of December 31, 2023 are expected to be reclassified to Product sales within 12 months. There were no discontinuances of cash flow hedges for the years presented. The cash flow effects of our derivative contracts for the years ended December 31, 2023, 2022 and 2021 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows. |
ACQUISITIONS
ACQUISITIONS | 12 Months Ended |
Dec. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
ACQUISITIONS | ACQUISITIONS CymaBay In February 2024, we entered into a definitive agreement to acquire all of the outstanding common stock of CymaBay Therapeutics, Inc. (“CymaBay”) and its lead product candidate, seladelpar, which is an investigational treatment for primary biliary cholangitis, for approximately $4.3 billion. Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of CymaBay’s common stock at a price of $32.50 per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer. Consummation of the tender offer is subject to a minimum tender of at least a majority of then-outstanding CymaBay shares, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Gilead plans to pay all cash consideration for the transaction. The tender offer is not subject to a financing condition. Upon closing, CymaBay will become a wholly-owned subsidiary. CymaBay’s lead program, seladelpar, is an investigational, oral, selective peroxisome proliferator-activated receptor delta agonist, shown to regulate critical metabolic and liver disease pathways. Based on data evaluating the efficacy and tolerability profile of seladelpar in more than 500 participants across Phase 2 and Phase 3 studies, a new drug application for seladelpar was submitted to FDA in December 2023. XinThera In May 2023, we closed an agreement to acquire XinThera, Inc. (“XinThera”), a privately held biotechnology company focused on small molecule drugs to treat cancer and immunologic diseases, for approximately $200 million in cash consideration, net of cash acquired. As a result, XinThera became our wholly-owned subsidiary. We accounted for the transaction as an asset acquisition and recorded a $170 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income in 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed. Under the agreement, the former shareholders of XinThera are eligible to receive performance-based development and regulatory milestone payments of up to approximately $760 million, with $50 million of that having been paid and charged primarily to Acquired in-process research and development expenses in 2023. Tmunity In February 2023, we closed an agreement to acquire Tmunity Therapeutics, Inc. (“Tmunity”), a clinical-stage, private biotechnology company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $300 million in cash consideration. As a result, Tmunity became our wholly-owned subsidiary. We accounted for the transaction as an asset acquisition and recorded a $244 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income in 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed, consisting primarily of deferred tax assets. Under the agreement, the former shareholders of Tmunity and the University of Pennsylvania are eligible to receive a mix of up to approximately $1.0 billion in potential future payments upon achievement of certain development, regulatory and sales-based milestones, as well as royalty payments on sales, with $25 million of that having been charged to Acquired in-process research and development expenses in 2023 and paid in January 2024. MiroBio On September 20, 2022, we acquired all of the outstanding share capital of MiroBio Ltd. (“MiroBio”), a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. As a result, MiroBio became our wholly-owned subsidiary. We accounted for the transaction as an asset acquisition and recorded a $389 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income in 2022. The remaining purchase price relates to various other assets acquired and liabilities assumed. MYR In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by European Medicines Agency (“EMA”) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition. The aggregate consideration for this acquisition of €1.3 billion (or $1.6 billion) primarily consisted of €1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to €300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date. See Note 3. Fair Value Measurements for additional information. The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: (in millions) Amount Intangible assets: Finite-lived intangible asset $ 845 Acquired IPR&D 1,190 Deferred income taxes, net (513) Other assets (and liabilities), net (187) Total identifiable net assets 1,335 Goodwill 226 Total consideration $ 1,561 Intangible Assets The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years. Acquired IPR&D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.19 billion as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. Deferred Income Taxes The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR. Goodwill The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes. The one-year measurement period was completed in the first quarter of 2022, with adjustments recorded to the fair values of assets acquired and liabilities assumed of $18 million. See Note 9. Goodwill and Intangible Assets for additional information. |
COLLABORATIONS AND OTHER ARRANG
COLLABORATIONS AND OTHER ARRANGEMENTS | 12 Months Ended |
Dec. 31, 2023 | |
Collaborative and Other Arrangements [Abstract] | |
COLLABORATIONS AND OTHER ARRANGEMENTS | COLLABORATIONS AND OTHER ARRANGEMENTS We enter into licensing and strategic collaborations and other similar arrangements with third parties for the research, development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. The financial terms of these arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments. Development milestone payments are recorded in our Consolidated Statements of Income as incurred, which is generally when the corresponding events become probable. Regulatory milestone payments are capitalized as intangible assets and amortized to Cost of goods sold over the term of the respective collaboration arrangement. Certain payments are contingent upon the occurrence of various future events that have a high degree of uncertainty. Arcellx In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future next-generation autologous and non-autologous products. In December 2023, we expanded the scope of the collaboration to include lymphomas and exercised our option to negotiate a license for Arcellx’s ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with these collaboration agreements, we recorded a combined $313 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income in 2023, primarily related to upfront payments, as well as a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Other long-term assets on our Consolidated Balance Sheets as of December 31, 2023. The companies will share development, clinical trial and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales. Arcellx is eligible to receive performance-based development and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future non-autologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well. Dragonfly In April 2022, we entered into a strategic research collaboration agreement (the “Dragonfly Collaboration Agreement”) with Dragonfly Therapeutics, Inc. (“Dragonfly”) to develop natural killer (“NK”) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we made a $300 million upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2022. In July 2023, we mutually agreed to terminate the DF7001 program. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs. Merck On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (“Merck”) to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, with other formulations potentially added to the collaboration as mutually agreed. The collaboration is initially focused on long-acting oral and injectable formulations. Under the terms of the agreement, as amended, Gilead and Merck will mostly share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the U.S., and Merck would lead commercialization in the European Union (“EU”) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the U.S. and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the years ended December 31, 2023, 2022 and 2021. No revenues have been recognized under the agreement for the years ended December 31, 2023, 2022 and 2021. We will also have the option to license certain of Merck’s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead’s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt out, in which case the non-exercising company will be paid a royalty. Arcus On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the “Collaboration Agreement”), with Gilead having the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction, and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the “Stock Purchase Agreements”). In November 2021, we exercised our options to three of Arcus’ clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving the $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $625 million was included within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2021. The collaboration opt-in payments of $725 million were recorded in Other current liabilities In May 2023, we again amended the Collaboration Agreement to initiate research programs against up to four targets jointly selected by the parties that are applicable to inflammatory diseases. As part of the amendment, we paid a $35 million upfront fee, which was charged to Acquired in-process research and development expenses on our Consolidated Statements of Income. Gilead may exercise an option to license each program at two separate, prespecified time points. If Gilead exercises its option at the earlier time point for the first two target programs, Arcus would be eligible to receive up to $420 million in future option and milestone payments and tiered royalties for each optioned program. For any other option exercise by Gilead for the four target programs, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the U.S. for optioned programs. Under the amended Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $189 million and $187 million of such costs in Research and development expenses on our Consolidated Statements of Income for the years ended December 31, 2023 and 2022, respectively. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus’s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. Under the amended Collaboration Agreement, we may also pay an additional $100 million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term. Under the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of 35% of the outstanding voting stock of Arcus over a five-year period ending in the third quarter of 2025. We were also subject to a three-year standstill, restricting certain other activity on our part, which expired in the second quarter of 2023. We have made various purchases of shares since the original closing of the agreement and, following our latest purchase in the second quarter of 2023, we owned a total of 14.8 million shares, which represented approximately 19.9% of the issued and outstanding voting stock of Arcus at that time. As of December 31, 2023, we had two designees on Arcus’ board of directors. In January 2024, we announced an amendment to the Collaboration Agreement with Arcus and made an additional equity investment in Arcus for $320 million, increasing our ownership to 33%. Under the amended Collaboration Agreement, we agreed to pay the $100 million fourth anniversary option continuation fee in 2024. We also increased our number of designees on Arcus’ board of directors to three. Pionyr In June 2020, we entered into a transaction with Pionyr Immuotherapeutics (“Pionyr”), a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate agreements, one related to the initial acquisition of a 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (the “Pionyr Merger and Option Agreements”) and a R&D service agreement. In March 2023, we terminated the R&D service agreement, waived our exclusive option to acquire Pionyr and certain other rights under the Pionyr Merger and Option Agreements and recorded a $70 million charge to Other income (expense), net on our Consolidated Statements of Income, writing off the full value of the option that had previously been recorded in Other long-term assets on our Consolidated Balance Sheets. We previously accounted for our investment in Pionyr using the equity method of accounting because our equity interest provided us with the ability to exercise significant influence over Pionyr. The carrying value of our equity method investment in Pionyr was zero as of December 31, 2022. In August 2023, Pionyr was acquired by Ikena Oncology, Inc. (“Ikena”), a publicly traded company, and our equity interest was converted to shares of Ikena stock. Tizona In July 2020, we entered into a transaction with Tizona Therapeutics, Inc. (“Tizona”), a privately held company developing cancer immunotherapies, which included entry into two separate agreements, one related to the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (the “Tizona Merger and Option Agreements”) and a development agreement. In September 2023, we terminated the development agreement, waived our exclusive option to acquire Tizona and certain other rights under the Tizona Merger and Option Agreements and recorded a $41 million charge to Other income (expense), net on our Consolidated Statements of Income, writing off the full value of the option that had previously been recorded in Other long-term assets on our Consolidated Balance Sheets. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. The carrying value of our equity method investment in Tizona was zero as of December 31, 2023 and 2022. Galapagos Filgotinib Collaboration In October 2023, we amended a previous agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, related to the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications, to terminate the global development cost-sharing arrangement and Galapagos’ obligation to pay tiered royalties to us on net sales in Europe. As a result, we wrote off the remaining $51 million balance of our related finite-lived intangible asset as discussed in Note 9. Goodwill and Intangible Assets. We had also previously paid Galapagos €160 million (or approximately $190 million) related to an agreement to terminate Galapagos’ right to receive any future milestone payments relating to filgotinib in Europe, with the full amount being expensed in 2020 and €110 million (or approximately $130 million) paid in 2021 and €50 million (or approximately $60 million) paid in 2022. Global Collaboration In August 2019, we closed an option, license and collaboration agreement (the “Galapagos Collaboration Agreement”) and a subscription agreement (the “Galapagos Subscription Agreement”), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos’ current and future product portfolio (other than filgotinib). Pursuant to the Galapagos Subscription Agreement, we purchased 6.8 million new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. With respect to programs in Galapagos’ current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. We have two designees appointed to Galapagos’ board of directors. Janssen Complera/Eviplera and Odefsey In 2009, we entered into a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of our Truvada and Janssen’s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen’s rilpivirine and our emtricitabine and tenofovir alafenamide (“Odefsey”). Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey. We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party. Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party’s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen’s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen’s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen’s share was $430 million, $483 million and $530 million for the years ended December 31, 2023, 2022 and 2021, respectively. Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years. Symtuza In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen’s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (“Gilead Compounds”). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party’s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza. Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. Japan Tobacco In 2005, Japan Tobacco, Inc. (“Japan Tobacco”) granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019. We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $167 million, $198 million and $250 million for the years ended December 31, 2023, 2022 and 2021, respectively. Under the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause. Everest In April 2019, Everest Medicines (“Everest”) and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia (the “Territories”). Gilead subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to be made to Gilead and was recorded as a $175 million finite-lived asset as part of the purchase accounting. In the fourth quarter of 2022, we reacquired all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, Gilead made $280 million in upfront termination payments to Everest, of which $84 million was made in 2022 and $196 million was made in 2023. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Income during the year ended December 31, 2022, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. Simultaneously, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories. Abingworth In December 2023, we entered into an arrangement with funds managed by Abingworth LLP (“Abingworth”) under which we will receive up to $210 million to co-fund our development costs for Trodelvy for non-small cell lung cancer in 2023 through 2026. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. In 2023, we received $50 million from Abingworth. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. If successful, upon regulatory approval in the U.S. for the specified indication, Abingworth will be eligible to receive an approval-based fixed milestone payment of up to $84 million and royalties based on the applicable net sales. |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY, PLANT AND EQUIPMENT | PROPERTY, PLANT AND EQUIPMENT The following table summarizes our Property, plant and equipment, net by asset type: December 31, (in millions) 2023 2022 Land and land improvements $ 561 $ 562 Buildings and improvements (including leasehold improvements) 4,328 4,390 Laboratory and manufacturing equipment 1,147 1,110 Office, computer equipment and other 1,069 880 Construction in progress 661 719 Subtotal 7,766 7,661 Less: accumulated depreciation 2,449 2,186 Total $ 5,317 $ 5,475 In 2023, we wrote off $381 million of property, plant and equipment related to changes in our manufacturing strategy. The write-offs related primarily to buildings, improvements and related equipment that were determined to be fully impaired based on the difference between fair value and the carrying amount as a result of our decision to no longer utilize the facilities. The following table summarizes our Property, plant and equipment, net by geography: December 31, (in millions) 2023 2022 U.S. $ 4,691 4,501 International (1) 626 973 Total $ 5,317 $ 5,475 ________________________________ (1) All individual international locations accounted for less than 10% of the total balances. |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS Goodwill The following table summarizes the changes in the carrying amount of Goodwill: December 31, (in millions) 2023 2022 Beginning balance $ 8,314 $ 8,332 Measurement period adjustments (1) — (18) Ending balance $ 8,314 $ 8,314 ________________________________ (1) In 2022, goodwill decreased by $18 million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired. Impairment Losses As of December 31, 2023, there were no accumulated goodwill impairment losses. Intangible Assets The following table summarizes our Intangible assets, net: December 31, 2023 December 31, 2022 (in millions) Gross Accumulated Foreign Currency Translation Adjustment Net Carrying Amount Gross Accumulated Foreign Currency Translation Adjustment Net Carrying Amount Finite-lived assets: Intangible asset – sofosbuvir $ 10,720 $ (7,050) $ — $ 3,670 $ 10,720 $ (6,350) $ — $ 4,370 Intangible asset – axicabtagene ciloleucel 7,110 (2,314) — 4,796 7,110 (1,908) — 5,202 Intangible asset – Trodelvy (1) 11,730 (2,002) — 9,728 5,630 (973) — 4,657 Intangible asset – Hepcludex 845 (243) — 602 845 (158) — 687 Other (2) 1,414 (827) 1 588 1,489 (733) 1 758 Total finite-lived assets 31,819 (12,436) 1 19,384 25,794 (10,121) 1 15,674 Indefinite-lived assets – IPR&D (1)(3) 7,070 — — 7,070 13,220 — — 13,220 Total intangible assets $ 38,889 $ (12,436) $ 1 $ 26,454 $ 39,014 $ (10,121) $ 1 $ 28,894 _______________________________ (1) In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023. (2) In the fourth quarter of 2023, in connection with our agreement to terminate our right to receive royalties from Galapagos related to net sales of filgotinib in Europe, we wrote-off the remaining $51 million balance of our related intangible asset. See Note 7. Collaborations and Other Arrangements for additional information. (3) In the fourth quarter of 2023, due to a change in anticipated timing of FDA approval, we recognized a $50 million partial impairment of our bulevirtide IPR&D intangible asset in In-process research and development impairments on our Consolidated Statements of Income. The remaining IPR&D intangible asset balance as of December 31, 2023 was comprised of $5.9 billion for non-small cell lung cancer (“NSCLC”) indications of Trodelvy and $1.1 billion for bulveritide. Amortization Expense Aggregate amortization expense related to finite-lived intangible assets was $2.3 billion, $1.8 billion and $1.7 billion for the years ended December 31, 2023, 2022 and 2021, respectively, primarily included in Cost of goods sold on our Consolidated Statements of Income. The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2023: (in millions) Amount 2024 $ 2,384 2025 2,378 2026 2,370 2027 2,370 2028 2,309 Thereafter 7,571 Total $ 19,384 Impairment Assessments No indicators of impairment were noted for the years ended December 31, 2023, 2022 and 2021, except as described in the “Intangible Assets” table above and under “2022 IPR&D Impairment” below. The weighted-average discount rates used in our quantitative assessments for IPR&D intangible assets during those years, other than for the assessment described below, were 7.5%, 7.5% and 6.5%, respectively. In January 2024, we announced that our Phase 3 EVOKE-01 study of Trodelvy evaluating sacituzumab govitecan-hziy (SG) did not meet its primary endpoint of overall survival (OS) in previously treated NSCLC. We believe that this new information represents an indicator of potential impairment in the first quarter of 2024 and, as a result, the fair value of the indefinite-lived IPR&D intangible asset related to Trodelvy may be below its carrying value. We expect to complete an interim impairment assessment of the related IPR&D intangible asset during the first quarter of 2024. To the extent that the estimated fair value is less than the carrying value of the asset, we will be required to record an impairment charge on our Consolidated Statements of Income during the three months ended March 31, 2024. Any such impairment charge, which we are unable to reasonably estimate at this time, could have a material impact on our consolidated results of operations. 2022 IPR&D Impairment In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&D intangible assets. Approximately $8.8 billion was assigned to IPR&D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (“HR+/HER2-”) breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (“third-line plus patients”). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&D intangible asset to $6.1 billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7 billion in In-process research and development impairments on our Consolidated Statements of Income during the three months ended March 31, 2022. |
OTHER FINANCIAL INFORMATION
OTHER FINANCIAL INFORMATION | 12 Months Ended |
Dec. 31, 2023 | |
Other Financial Information [Abstract] | |
OTHER FINANCIAL INFORMATION | OTHER FINANCIAL INFORMATION Accounts Receivable, Net The following table summarizes our Accounts receivable, net: December 31, (in millions) 2023 2022 Accounts receivable $ 5,495 $ 5,464 Less: allowances for chargebacks 679 549 Less: allowances for cash discounts and other 101 83 Less: allowances for credit losses 56 55 Accounts receivable, net $ 4,660 $ 4,777 The majority of our trade accounts receivable arises from product sales in the U.S. and Europe. Inventories The following table summarizes our Inventories: December 31, (in millions) 2023 2022 Raw materials $ 1,246 $ 1,177 Work in process 847 577 Finished goods 1,272 1,066 Total $ 3,366 $ 2,820 Reported as: Inventories $ 1,787 $ 1,507 Other long-term assets (1) 1,578 1,313 Total $ 3,366 $ 2,820 _______________________________ (1) Amounts primarily consist of raw materials. Other Current Liabilities The following table summarizes the components of Other current liabilities December 31, (in millions) 2023 2022 Compensation and employee benefits $ 1,201 $ 1,018 Income taxes payable 1,208 959 Allowance for sales returns 387 422 Other 2,334 2,182 Other current liabilities $ 5,130 $ 4,580 Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax: (in millions) Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax Total Balance as of December 31, 2020 $ 51 $ 2 $ (113) $ (60) Net unrealized (loss) gain (38) (6) 129 85 Reclassifications to net income — — 58 58 Other comprehensive (loss) income, net (38) (6) 187 143 Balance as of December 31, 2021 $ 13 $ (4) $ 74 $ 83 Net unrealized (loss) gain $ (11) $ (30) $ 130 $ 88 Reclassifications to net income — 1 (171) (170) Other comprehensive loss, net (11) (29) (41) (81) Balance as of December 31, 2022 $ 2 $ (33) $ 33 $ 2 Net unrealized gain (loss) $ 60 $ 26 $ (12) $ 75 Reclassifications to net income — 2 (51) (49) Other comprehensive income (loss), net 60 28 (62) 26 Balance as of December 31, 2023 $ 62 $ (5) $ (29) $ 28 Restructuring During 2023, we incurred restructuring charges totaling $527 million primarily due to changes in our manufacturing strategy which included a decision to no longer utilize certain facilities. As a result of this decision, we determined that the related assets were fully impaired based on the difference between fair value and the carrying amount. The total charges consisted of write-offs of manufacturing assets of $381 million, write-offs of inventory of $89 million and other costs of $57 million. As a result, we recorded a $479 million charge to Cost of goods sold, a $20 million charge to Research and development expenses and a $28 million charge to Selling, general and administrative expenses on our Consolidated Statements of Income. |
DEBT AND CREDIT FACILITIES
DEBT AND CREDIT FACILITIES | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
DEBT AND CREDIT FACILITIES | DEBT AND CREDIT FACILITIES The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate December 31, 2023 December 31, 2022 Senior Unsecured September 2016 September 2023 2.50% $ — $ 749 Senior Unsecured September 2020 September 2023 0.75% — 1,498 Senior Unsecured March 2014 April 2024 3.70% 1,750 1,748 Senior Unsecured November 2014 February 2025 3.50% 1,749 1,748 Senior Unsecured September 2015 March 2026 3.65% 2,744 2,742 Senior Unsecured September 2016 March 2027 2.95% 1,248 1,247 Senior Unsecured September 2020 October 2027 1.20% 747 747 Senior Unsecured September 2020 October 2030 1.65% 994 993 Senior Unsecured September 2023 October 2033 5.25% 992 — Senior Unsecured September 2015 September 2035 4.60% 993 993 Senior Unsecured September 2016 September 2036 4.00% 743 742 Senior Unsecured September 2020 October 2040 2.60% 988 988 Senior Unsecured December 2011 December 2041 5.65% 996 996 Senior Unsecured March 2014 April 2044 4.80% 1,737 1,736 Senior Unsecured November 2014 February 2045 4.50% 1,734 1,733 Senior Unsecured September 2015 March 2046 4.75% 2,222 2,221 Senior Unsecured September 2016 March 2047 4.15% 1,729 1,728 Senior Unsecured September 2020 October 2050 2.80% 1,478 1,477 Senior Unsecured September 2023 October 2053 5.55% 988 — Total senior unsecured notes 23,834 24,088 Liability related to future royalties 1,153 1,141 Total debt, net 24,987 25,229 Less: Current portion of long-term debt and other obligations, net 1,798 2,273 Total Long-term debt, net $ 23,189 $ 22,957 Senior Unsecured Notes In September 2023, we issued $2.0 billion aggregate principal amount of senior unsecured notes in a registered offering consisting of $1.0 billion principal amount of 5.25% senior unsecured notes due October 2033 and $1.0 billion principal amount of 5.55% senior unsecured notes due October 2053. Additionally, in September 2023, we repaid at maturity $2.25 billion of principal balance related to our senior unsecured notes due September 2023. Our senior unsecured notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium, which are defined in the terms of the notes. The senior unsecured notes also have a par call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from two In the event of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody’s Investors Service, Inc. and S&P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December 31, 2023 and 2022, we were not in violation of any covenants. Liability Related to Future Royalties In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (“RPI”), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. Revolving Credit Facilities In June 2020, we entered into a $2.5 billion five-year revolving credit facility maturing in June 2025 (the “2020 Revolving Credit Facility”). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December 31, 2023 and 2022, there were no amounts outstanding under the 2020 Revolving Credit Facility. The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December 31, 2023, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Term SOFR plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty. Contractual Maturities of Financing Obligations The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December 31, 2023: (in millions) Amount 2024 $ 1,750 2025 1,750 2026 2,750 2027 2,000 2028 — Thereafter 15,750 Total $ 24,000 |
LEASES
LEASES | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
LEASES | LEASES Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December 31, 2023 and 2022, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $165 million, $162 million and $156 million for the years ended December 31, 2023, 2022 and 2021, respectively. The following table summarizes balance sheet and other information related to our operating leases: December 31, (in millions, except weighted average amounts) Classification 2023 2022 Right-of-use assets, net Other long-term assets $ 581 $ 505 Lease liabilities – current Other current liabilities $ 125 $ 111 Lease liabilities – noncurrent Other long-term obligations $ 546 $ 467 Weighted average remaining lease term 7.5 years 8.1 years Weighted average discount rate 3.22 % 2.80 % The following table summarizes other supplemental information related to our operating leases: Year Ended December 31, (in millions) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities $ 88 $ 98 Right-of-use assets obtained in exchange for lease liabilities (1) $ 214 $ 97 _______________________________ (1) These represent noncash activities and were therefore not included on our Consolidated Statements of Cash Flows. The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December 31, 2023: (in millions) Amount 2024 $ 143 2025 123 2026 95 2027 76 2028 70 Thereafter 257 Total undiscounted lease payments 763 Less: imputed interest 92 Total discounted lease payments $ 671 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Legal Proceedings We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. We recorded an expense of $525 million in 2023 in Selling, general and administrative expenses on our Consolidated Statements of Income for settlements with certain plaintiffs in the HIV antitrust litigation, which we paid in the second half of 2023. We did not have any material accruals for the matters described below as of December 31, 2023 and December 31, 2022. Litigation Relating to Pre-Exposure Prophylaxis In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, “HHS Patents”) by the Patent Trial and Appeal Board (“PTAB”). The HHS Patents are assigned to the U.S. Department of Health and Human Services (“HHS”) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (“TDF”) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (“PrEP”). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a lawsuit against the U.S. federal government in the U.S. Court of Federal Claims (“CFC”), alleging breach of three material transfer agreements (“MTAs”) related to the research underlying the HHS Patents and two clinical trial agreements (“CTAs”) by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the CFC was held in June 2022, and in November 2022, the CFC determined that the government breached the MTAs. In January 2024, the CFC found the government liable for breach of both CTAs. In May 2023, the District Court held a trial regarding the government’s patent infringement claims, and the jury rendered a full defense verdict in favor of Gilead, finding that the asserted claims of the HHS Patents are invalid and the HHS patents are not infringed. The government has filed post-trial motions, and we expect the District Court to issue a decision on those motions during the first quarter of 2024. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached its contracts with Gilead, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada’s use for PrEP and post-exposure prophylaxis because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A separate trial at the CFC to determine the damages Gilead is owed based on the government’s breach has yet to be scheduled. Litigation with Generic Manufacturers As part of the approval process for some of our products, FDA granted us a New Chemical Entity (“NCE”) exclusivity period during which other manufacturers’ applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (“ANDA”), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product’s approval. In October 2021, we received a letter from Lupin Ltd. (“Lupin”) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen and Janssen Products, L.P., filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (“Apotex”) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen and Janssen Products, L.P., filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. The cases against Lupin and Apotex have been consolidated into a single trial scheduled for May 2024. Starting in March 2022, we received letters from Lupin, Laurus Labs (“Laurus”) and Cipla Ltd. (“Cipla”), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of the adult dosage strength of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of four of the six patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for October 2025. Additionally, in November 2023, we received a letter from Cipla indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of the pediatric dosage strength of Biktarvy. Cipla challenged the validity of two of the patents listed in the Orange Book as associated with Biktarvy. We filed a separate lawsuit against Cipla in December 2023 in the U.S. District Court of Delaware. In June 2023, we received a letter from Apotex indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Genvoya. In July 2023, we filed a patent infringement lawsuit against Apotex in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. This case has been consolidated with the Symtuza matters discussed above, and a trial has been scheduled for June 2024. Antitrust and Consumer Protection We, along with Bristol-Myers Squibb Company (“BMS”), Johnson & Johnson, Inc. (“Johnson & Johnson”), and Teva Pharmaceutical Industries Ltd. (“Teva”) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs consisting of retail pharmacies, individual health plans and United Healthcare, filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the classes. These cases have been coordinated with the class actions. In March 2023, the District Court granted our motion to hold separate trials as to (i) the allegations against us and Teva seeking monetary damages relating to Truvada and Atripla (“Phase I”) and (ii) the allegations against us and, in part, Johnson & Johnson, seeking monetary damages and injunctive relief relating to Complera (“Phase II”). In May 2023, we settled claims with the direct purchaser class and the retailer opt-out plaintiffs for $525 million, which we paid in the second half of 2023. The settlement agreements are not an admission of liability or fault by us, and are subject to a number of other conditions including, with respect to the preliminary settlement agreement between us and the direct purchaser class, court approval. In June 2023, the jury returned a complete verdict in Gilead’s favor on the remaining plaintiffs’ Phase I allegations. In November 2023, the court denied plaintiffs’ motion to set aside the verdict. Plaintiffs have indicated they intend to appeal the jury verdict. Trial on the Phase II claims has not yet been scheduled. Plaintiffs and the Phase I defendants have requested that the court stay Phase II pending any appeal of Phase I. While we intend to vigorously defend against the Phase II claims, we cannot predict the ultimate outcome. If plaintiffs are successful in their Phase II claims, we could be required to pay monetary damages or could be subject to permanent injunctive relief in favor of plaintiffs. In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief. In September 2023, we filed a motion for judgment on the pleadings to preclude Aetna from re-litigating claims that were dismissed at summary judgment in the above class action cases. The motion remains pending. In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, “Cipla Defendants”), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (“Jacksonville Trust”) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs sought damages, permanent injunctive relief and other relief. In January 2024, we settled plaintiffs’ claim for a de minimis fee. In February 2021, we, along with BMS and Teva, were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief. We moved to dismiss the case based on lack of personal jurisdiction and, in July 2023, the New Mexico Supreme Court remanded the case back to the trial court for limited jurisdictional discovery. We intend to vigorously defend ourselves in these actions, however, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs, which may result in a material, adverse effect on our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable. Product Liability We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California and Missouri, involve more than 25,000 active plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed pending the conclusion of appellate proceedings in the California First District Court of Appeal and California Supreme Court. The first bellwether trial in California federal court is scheduled to begin in November 2024. We intend to vigorously defend ourselves in these actions, however, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages, which may result in a material, adverse effect on our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable. Government Investigation In 2017, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry. Qui Tam Litigation A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government’s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead’s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The lawsuit seeks all available relief under these statutes. Health Choice Advocates, LLC (“Health Choice”) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General’s Office’s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court’s dismissal. Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. The lawsuit alleged that Gilead violated the Texas Medicare Fraud Prevention Act (“TMFPA”) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit sought all available relief under the TMFPA. Health Choice voluntarily dismissed the case without prejudice in August 2023, and commenced a new action in October 2023, asserting largely identical allegations and claims. In the newly filed action, the Texas Attorney General has intervened as a plaintiff. We intend to vigorously defend ourselves in these actions, however, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages, which may result in a material, adverse effect on our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable. Other Matters We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that it is probable or reasonably possible that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows. |
EMPLOYEE BENEFITS
EMPLOYEE BENEFITS | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
EMPLOYEE BENEFITS | EMPLOYEE BENEFITS Stock-Based Compensation Equity Incentive Plans Summary In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the “2004 Plan”). As part of the Forty Seven, Inc. acquisition in 2020, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the “2018 Plan”). As part of the Immunomedics acquisition in 2020, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan, which we subsequently merged into the 2004 Plan. In May 2022, our stockholders approved and we adopted the Gilead Sciences, Inc. 2022 Equity Incentive Plan (the “2022 Plan”). The 2022 Plan authorized the issuance of a total of 132 million shares of common stock. No awards may be granted under the 2004 Plan or the 2018 Plan since the approval of the 2022 Plan. These are broad-based incentive plans that provide for the grant of equity-based awards, including RSUs, PSUs, stock options and other restricted stock and performance awards, to employees, directors and consultants. As of December 31, 2023, a total of 82 million shares remain available for future grant under the 2022 Plan. RSUs We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over three PSUs We grant PSUs that vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. PSUs have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit. Stock Options Option grants are designated as either non-statutory or incentive stock options. The exercise price of stock options may not be less than the fair market value of our common stock on the grant date and no stock option may have a term in excess of 10 years. Employee stock options generally vest over three ESPP Summary Under our ESPP, employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature. ESPP purchases are settled with common stock from the ESPP’s previously authorized and available pool of shares. A total of 104 million shares of common stock have been authorized for issuance under the ESPP, and there were 26 million shares available for issuance under the ESPP as of December 31, 2023. Stock-Based Compensation Expense The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income, classified by award type and expense type: Year Ended December 31, (in millions) 2023 2022 2021 RSUs $ 666 $ 557 $ 558 PSUs 32 25 17 Stock options 30 28 29 ESPP 37 26 31 Acquisition-related expense (1) 29 8 — Stock-based compensation expense included in total costs and expenses $ 796 $ 645 $ 635 ________________________________ (1) Accelerated post-acquisition stock-based compensation expenses of $19 million and $10 million related to the 2023 XinThera and Tmunity acquisitions, respectively, and $8 million related to the 2022 MiroBio acquisition. Year Ended December 31, (in millions) 2023 2022 2021 Cost of goods sold $ 57 $ 46 $ 40 Research and development expenses 377 285 287 Selling, general and administrative expenses 361 313 308 Stock-based compensation expense included in total costs and expenses 796 645 635 Income tax effect (165) (91) (100) Stock-based compensation expense, net of tax $ 630 $ 553 $ 535 RSUs The following tables summarize our RSU activity: RSUs (in millions, except per share amounts) Shares Weighted- Outstanding as of December 31, 2022 23.6 $ 63.62 Granted 11.5 $ 79.66 Vested (10.7) $ 63.78 Forfeited (1.6) $ 69.31 Outstanding as of December 31, 2023 22.7 $ 71.24 Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Weighted-average grant date fair value of RSUs granted $ 79.66 $ 60.36 $ 65.42 Total fair value of RSUs as of the respective vesting dates $ 849 $ 554 $ 463 As of December 31, 2023, there was $1 billion of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of 2.2 years. PSUs The following tables summarize our PSU activity: PSUs (in millions, except per share amounts) Shares Weighted- Outstanding as of December 31, 2022 1.0 $ 64.28 Granted 0.5 $ 81.39 Vested (0.4) $ 79.62 Forfeited (0.1) $ 59.95 Outstanding as of December 31, 2023 1.0 $ 67.48 Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Weighted-average grant date fair value of PSUs granted $ 81.39 $ 60.04 $ 71.31 Total fair value of PSUs as of the respective vesting dates $ 35 $ 14 $ 8 As of December 31, 2023, there was $27 million of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of 1.2 years. Stock Options The following tables summarize activity and other information related to our stock options: Shares Weighted- Weighted-Average Aggregate Intrinsic Value (in millions) (1) Outstanding as of December 31, 2022 14.4 $ 67.69 Granted 2.1 $ 79.53 Exercised (1.5) $ 64.72 Forfeited (0.5) $ 66.91 Expired (0.2) $ 92.76 Outstanding as of December 31, 2023 14.3 $ 69.38 6.10 $ 177 Exercisable as of December 31, 2023 9.2 $ 70.00 4.97 $ 112 Expected to vest, net of estimated forfeitures as of December 31, 2023 4.8 $ 68.19 8.16 $ 61 ________________________________ (1) Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable . Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Weighted-average grant date fair value of stock options granted $ 16.11 $ 9.08 $ 10.05 Total intrinsic value of options exercised $ 25 $ 59 $ 48 We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards: Year Ended December 31, 2023 2022 2021 Expected volatility 26 % 27 % 29 % Expected terms in years 5 5 5 Risk-free interest rate 4.1 % 1.9 % 0.8 % Expected dividend yield 3.5 % 4.3 % 4.4 % As of December 31, 2023, there was $46 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.2 years. ESPP The following table summarizes our ESPP activity: Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Shares issued 2 2 2 Amount paid by employees for shares $ 129 $ 103 $ 111 Weighted-average grant date fair value of ESPP shares granted $ 17.31 $ 13.40 $ 14.58 Total fair value of ESPP shares as of the respective vesting dates $ 45 $ 21 $ 23 We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards: Year Ended December 31, 2023 2022 2021 Expected volatility 24 % 23 % 25 % Expected terms in years 0.5 0.5 0.5 Risk-free interest rate 5.1 % 1.8 % 0.1 % Expected dividend yield 3.7 % 4.5 % 4.4 % Deferred Compensation We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the “Gilead Sciences 401k Plan”). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $208 million, $176 million and $166 million for the years ended December 31, 2023, 2022 and 2021, respectively. |
EARNINGS PER SHARE
EARNINGS PER SHARE | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
EARNINGS PER SHARE | EARNINGS PER SHARE The following table shows the calculation of basic and diluted earnings per share attributable to Gilead: Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Net income attributable to Gilead $ 5,665 $ 4,592 $ 6,225 Shares used in basic earnings per share attributable to Gilead calculation 1,248 1,255 1,256 Dilutive effect of stock options and equivalents 10 7 6 Shares used in diluted earnings per share attributable to Gilead calculation 1,258 1,262 1,262 Basic earnings per share attributable to Gilead 4.54 3.66 4.96 Diluted earnings per share attributable to Gilead 4.50 3.64 4.93 Potential shares of common stock excluded from the computation of Diluted earnings per share attributable to Gilead because their effect would have been antidilutive were 4 million, 12 million and 15 million for the years ended December 31, 2023, 2022 and 2021, respectively. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES Income before income taxes consists of the following: Year Ended December 31, (in millions) 2023 2022 2021 Domestic $ 5,467 $ 4,439 $ 8,587 Foreign 1,392 1,375 (309) Income before income taxes $ 6,859 $ 5,814 $ 8,278 Income tax expense consists of the following: Year Ended December 31, (in millions) 2023 2022 2021 Federal: Current $ (1,781) $ (2,539) $ (1,776) Deferred 1,126 1,502 250 (655) (1,037) (1,526) State: Current (80) (32) (228) Deferred (170) 154 (185) (250) 122 (413) Foreign: Current (381) (232) (185) Deferred 39 (101) 47 (342) (333) (138) Income tax expense $ (1,247) $ (1,248) $ (2,077) The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows: Year Ended December 31, 2023 2022 2021 Federal statutory rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit 2.3 % (2.0) % 2.5 % Foreign earnings at different rates (0.2) % (0.6) % (0.3) % Research and other credits (4.3) % (2.7) % (1.6) % US tax on foreign earnings 1.0 % 2.7 % 1.1 % Foreign-derived intangible income deduction (2.1) % (3.8) % (1.6) % Tax examinations (4.7) % (0.2) % (0.7) % Acquired IPR&D & related charges 1.3 % 1.4 % — % Changes in valuation allowance 0.9 % 1.2 % 1.5 % Non-taxable unrealized loss on investment 0.2 % 0.7 % 1.8 % Other 2.8 % 3.8 % 1.4 % Effective tax rate 18.2 % 21.5 % 25.1 % Significant components of our deferred tax assets and liabilities are as follows: December 31, (in millions) 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 417 $ 430 Stock-based compensation 94 95 Reserves and accruals not currently deductible 644 645 Excess of tax basis over book basis of intangible assets 1,041 1,067 Upfront and milestone payments 1,271 1,298 Research and other credit carryforwards 283 233 Equity investments 221 196 Liability related to future royalties 296 278 Capitalized R&D expenditures 1,623 784 Other, net 320 263 Total deferred tax assets before valuation allowance 6,210 5,289 Valuation allowance (663) (599) Total deferred tax assets 5,547 4,690 Deferred tax liabilities: Property, plant and equipment (274) (234) Excess of book basis over tax basis of intangible assets (5,481) (5,728) Other (184) (160) Total deferred tax liabilities (5,939) (6,122) Net deferred tax assets (liabilities) $ (392) $ (1,432) The valuation allowance increased by $64 million and $79 million for the years ended December 31, 2023 and December 31, 2022, respectively, primarily due to unrealized losses on our equity investments which are subject to a full valuation allowance. As of December 31, 2023, we had U.S. federal net operating loss and tax credit carryforwards of approximately $388 million and $12 million, respectively, which will start to expire in 2025 and 2024, respectively, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $2.7 billion and $1.0 billion, respectively, which will start to expire in 2024, if not utilized. Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. We file federal, state and foreign income tax returns in the U.S. and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years. Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions. Of the total unrecognized tax benefits, $929 million and $946 million as of December 31, 2023 and 2022, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax benefit of $35 million, income tax benefit of $3 million, and income tax expense of $41 million on our Consolidated Statements of Income for the years ended December 31, 2023, 2022 and 2021, respectively. Accrued interest and penalties related to unrecognized tax benefits were $180 million and $215 million as of December 31, 2023 and 2022, respectively. We believe that it is reasonably possible that our unrecognized tax benefits may further decrease by approximately $400 million in the next 12 months due to potential resolutions with a tax authority. The following is a rollforward of our total gross unrecognized tax benefits: Year Ended December 31, (in millions) 2023 2022 2021 Beginning balance $ 1,959 $ 1,713 $ 1,614 Tax positions related to current year: Additions 265 129 147 Reductions — — — Tax positions related to prior years: Additions 109 225 161 Reductions (315) (31) (179) Settlements (42) (10) (28) Lapse of statute of limitations (13) (68) (2) Ending balance $ 1,962 $ 1,959 $ 1,713 In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. Federal income tax payable for transition tax was $2.4 billion and $3.5 billion as of December 31, 2023 and 2022, respectively. The following table summarizes the anticipated timing of payments associated with this transition tax as of December 31, 2023: (in millions) Amount 2024 $ 1,182 2025 1,252 Total $ 2,434 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS We have evaluated subsequent events and determined that, in addition to those already disclosed elsewhere in the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K, the following events or transactions met the definition of a subsequent event for purposes of recognition or disclosure: Dividend |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Pay vs Performance Disclosure | |||
Net income attributable to Gilead | $ 5,665 | $ 4,592 | $ 6,225 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended | 12 Months Ended |
Dec. 31, 2023 shares | Dec. 31, 2023 shares | |
Trading Arrangements, by Individual | ||
Non-Rule 10b5-1 Arrangement Adopted | false | |
Rule 10b5-1 Arrangement Terminated | false | |
Non-Rule 10b5-1 Arrangement Terminated | false | |
Merdad V. Parsey [Member] | ||
Trading Arrangements, by Individual | ||
Material Terms of Trading Arrangement | On November 9, 2023, Merdad V. Parsey, M.D., PhD., our Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell, subject to certain conditions, through November 8, 2024: (a) up to 29,393 shares of our common stock; (b) the total number of shares of our common stock sufficient to cover costs and fees and to satisfy applicable withholding taxes in connection with the exercise of 64,376 stock options; and (c) 25% of net shares of our common stock to be issued to Dr. Parsey after the satisfaction of applicable withholding taxes following the potential vesting and settlement of up to 56,624 performance shares. | |
Name | Merdad V. Parsey | |
Title | Chief Medical Officer | |
Rule 10b5-1 Arrangement Adopted | true | |
Adoption Date | November 9, 2023 | |
Arrangement Duration | 365 days | |
Merdad V. Parsey Rule Trading Arrangement, Common Stock [Member] | Merdad V. Parsey [Member] | ||
Trading Arrangements, by Individual | ||
Aggregate Available | 29,393 | 29,393 |
Merdad V. Parsey Rule Trading Arrangement, Stock Options [Member] | Merdad V. Parsey [Member] | ||
Trading Arrangements, by Individual | ||
Aggregate Available | 64,376 | 64,376 |
Merdad V. Parsey Rule Trading Arrangement, Performance Shares [Member] | Merdad V. Parsey [Member] | ||
Trading Arrangements, by Individual | ||
Aggregate Available | 56,624 | 56,624 |
ORGANIZATION AND SUMMARY OF S_2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and any variable interest entities (“VIEs”) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For any consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the attributable economic or ownership interest retained in such entities by the respective noncontrolling parties. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. |
Revenue Recognition | Revenue Recognition Product Sales We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, patient co-pay assistance, prompt pay discounts, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation. Gross-to-Net Deductions Rebates and Chargebacks Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us. Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information. Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets. Patient Co-Pay Assistance Co-pay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. Our accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end. Cash Discounts We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. Distributor Fees Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales. Allowance for Sales Returns Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis. Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. Royalty, Contract and Other Revenues Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied. |
Research and Development Expenses | Research and Development Expenses Research and development expenses are recorded when incurred and consist primarily of personnel costs including salaries, benefits and stock-based compensation expense, infrastructure, materials and supplies and other support costs, research and clinical studies performed by contract research organizations (“CROs”) and our collaboration partners and other outside services. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses. Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided. |
Acquired In Process Research and Development Expenses | Acquired In-Process Research and Development Expenses |
Selling, General and Administrative Expenses | Selling, General and Administrative Expenses Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, and sales, marketing and advertising expenses, as well as other general and administrative costs related to finance, human resources, legal and other administrative activities. |
Stock-Based Compensation | Stock-Based Compensation We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (“RSUs”), performance share units (“PSUs”) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the “ESPP”). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability. The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments. |
Earnings Per Share | Earnings Per Share Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method. |
Cash and Cash Equivalents | Cash and Cash Equivalents |
Marketable Debt Securities | Marketable Debt Securities |
Accounts Receivable | Accounts Receivable |
Inventories | Inventories Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. |
Equity Securities | Equity Securities Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income. For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment. |
Property, Plant and Equipment | Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: Description Estimated Useful Life Buildings and improvements Shorter of 35 years or useful life Laboratory and manufacturing equipment 4-10 Office, computer equipment and other 3-15 Leasehold improvements Shorter of useful life or lease term See “Impairment of Long-Lived Assets” for additional information. |
Leases | Leases We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term. We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less. |
Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration | Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See “Impairment of Long-Lived Assets” for additional information. In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset’s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors. In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets |
Derivatives | Derivatives We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income. Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income. |
Contingencies | Contingencies We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. |
Income Taxes | Income Taxes Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (“UTB”) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred. |
Stock Repurchases | Stock Repurchases We use the par value method of accounting for our stock repurchases made under repurchase programs. Under the par value method, we record the par value of the shares repurchased to Common stock and the historical issuance cost over par value of the shares repurchased to Additional paid-in capital. The excess of the cost of the shares repurchased over these two amounts is then recorded to Retained earnings . |
Foreign Currency Translation and Transaction | Foreign Currency Translation and Transactions Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income. |
Fair Value Measurements | Fair Value Measurements We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks. We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: • Level 1 inputs include quoted prices in active markets for identical assets or liabilities; • Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and • Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. |
Fair Value Measurements | Level 2 Inputs Available-for-Sale Debt Securities For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. Foreign Currency Derivative Contracts Our foreign currency derivative contracts have maturities of 18 months or less and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P Global Ratings, Moody’s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by utilizing an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (“SOFR”) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals. Level 3 Inputs Contingent Consideration Liability In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to €300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (“FDA”) approval of Hepcludex until the related contingency is resolved. |
Recently Issued Accounting Pronouncements Not Yet Adopted | Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments in the update and all existing segment disclosures in Topic 280. This guidance will be applied retrospectively, and we plan to adopt it beginning with our 2024 annual report to be filed in early 2025 and all quarterly and annual reports thereafter. As we have a single reportable segment, we expect the adoption of this standard to result in increased disclosures in our Notes to Consolidated Financial Statements. In December 2023, FASB issued ASU No. 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. This guidance requires prospective application and permits retrospective application to prior periods presented. We plan to adopt it beginning with our 2025 annual report to be filed in early 2026. We expect the adoption of this standard to result in increased disclosures in our Notes to Consolidated Financial Statements. |
ORGANIZATION AND SUMMARY OF S_3
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Property, Plant and Equipment, Estimated Useful Life | Estimated useful lives in years are generally as follows: Description Estimated Useful Life Buildings and improvements Shorter of 35 years or useful life Laboratory and manufacturing equipment 4-10 Office, computer equipment and other 3-15 Leasehold improvements Shorter of useful life or lease term |
REVENUES (Tables)
REVENUES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Summary of Disaggregation of Revenue | The following table summarizes our Total revenues: Year Ended December 31, 2023 Year Ended December 31, 2022 Year Ended December 31, 2021 (in millions) U.S. Europe Other Total U.S. Europe Other Total U.S. Europe Other Total Product sales: HIV Biktarvy $ 9,692 $ 1,253 $ 905 $ 11,850 $ 8,510 $ 1,103 $ 777 $ 10,390 $ 7,049 $ 969 $ 606 $ 8,624 Complera/Eviplera 47 70 12 129 74 113 13 200 102 142 14 258 Descovy 1,771 100 114 1,985 1,631 118 123 1,872 1,397 164 139 1,700 Genvoya 1,752 205 103 2,060 1,983 284 136 2,404 2,267 391 221 2,879 Odefsey 1,012 294 44 1,350 1,058 364 47 1,469 1,076 440 52 1,568 Stribild 72 21 8 101 88 29 10 127 132 43 14 189 Truvada 82 13 19 114 113 15 18 147 314 22 35 371 Revenue share - Symtuza (1) 382 133 13 529 348 168 14 530 355 165 11 531 Other HIV (2) 37 12 7 56 15 24 17 57 136 30 29 195 Total HIV 14,848 2,102 1,226 18,175 13,820 2,219 1,155 17,194 12,828 2,366 1,121 16,315 Oncology Cell Therapy Tecartus 245 110 15 370 221 75 3 299 136 40 — 176 Yescarta 811 547 140 1,498 747 355 57 1,160 406 253 36 695 Total Cell Therapy 1,055 658 156 1,869 968 430 60 1,459 542 293 36 871 Trodelvy 777 217 68 1,063 525 143 12 680 370 10 — 380 Total Oncology 1,833 875 224 2,932 1,494 573 73 2,139 912 303 36 1,251 Liver Disease Chronic hepatitis C virus (“HCV”) Ledipasvir/ Sofosbuvir (3) 39 12 19 70 46 17 51 115 84 31 97 212 Sofosbuvir/Velpatasvir (4) 859 323 355 1,537 844 355 331 1,530 815 316 331 1,462 Other HCV (5) 104 43 12 160 115 40 10 166 119 74 14 207 Total HCV 1,002 378 386 1,767 1,005 413 392 1,810 1,018 421 442 1,881 Chronic hepatitis B virus (“HBV”) / Chronic hepatitis delta virus (“HDV”) Vemlidy 410 38 414 862 429 35 379 842 384 34 396 814 Viread 8 22 52 83 6 23 62 91 11 28 72 111 Other HBV/HDV (6) — 72 — 72 — 55 — 55 2 42 — 44 Total HBV/HDV 418 133 466 1,017 435 112 441 988 397 104 468 969 Total Liver Disease 1,421 511 852 2,784 1,440 525 833 2,798 1,415 525 910 2,850 Veklury 972 408 805 2,184 1,575 702 1,628 3,905 3,640 1,095 830 5,565 Other AmBisome 43 260 189 492 57 258 182 497 39 274 227 540 Letairis 142 — — 142 196 — — 196 206 — — 206 Other (7) 118 40 66 225 135 65 53 253 136 115 30 281 Total Other 304 301 255 859 388 323 235 946 381 389 257 1,027 Total product sales 19,377 4,197 3,361 26,934 18,716 4,342 3,924 26,982 19,176 4,678 3,154 27,008 Royalty, contract and other revenues 62 114 7 182 168 127 4 299 91 196 10 297 Total revenues $ 19,438 $ 4,310 $ 3,368 $ 27,116 $ 18,884 $ 4,469 $ 3,928 $ 27,281 $ 19,267 $ 4,874 $ 3,164 $ 27,305 _______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 7. Collaborations and Other Arrangements for additional information. (2) Includes Atripla, Emtriva, Sunlenca and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig. |
Summary of Revenues from Major Customers | The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues: Year Ended December 31, (as a percentage of total revenues) 2023 2022 2021 Cardinal Health, Inc. 26 % 25 % 22 % Cencora, Inc. (formerly known as AmerisourceBergen Corporation) 19 % 18 % 23 % McKesson Corporation 21 % 20 % 20 % |
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods | The following table summarizes revenues recognized from performance obligations satisfied in prior years: Year Ended December 31, (in millions) 2023 2022 2021 Revenue share with Janssen (1) and royalties for licenses of intellectual property $ 680 $ 783 $ 851 Changes in estimates $ 340 $ 582 $ 856 ________________________________ (1) See Note 7. Collaborations and Other Arrangements for additional information. |
Summary of Contract Balances | The following table summarizes our contract balances: December 31, (in millions) 2023 2022 Contract assets (1) $ 117 $ 171 Contract liabilities (2) $ 109 $ 102 ________________________________ (1) Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation. (2) Generally results from receipt of advance payment before our performance under the contract. |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Summary of Assets and Liabilities Measured at Fair Value | The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: December 31, 2023 December 31, 2022 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Available-for-sale debt securities: U.S. treasury securities $ 426 $ — $ — $ 426 $ 410 $ — $ — $ 410 U.S. government agencies securities — 127 — 127 — 35 — 35 Non-U.S. government securities — 10 — 10 — 34 — 34 Certificates of deposit — 45 — 45 — 54 — 54 Corporate debt securities — 1,451 — 1,451 — 1,427 — 1,427 Residential mortgage and asset-backed securities — 367 — 367 — 333 — 333 Equity securities: Money market funds 4,465 — — 4,465 3,831 — — 3,831 Publicly traded equity securities (1) 1,458 — — 1,458 1,197 — — 1,197 Deferred compensation plan 284 — — 284 220 — — 220 Foreign currency derivative contracts — 7 — 7 — 60 — 60 Total $ 6,633 $ 2,007 $ — $ 8,639 $ 5,658 $ 1,943 $ — $ 7,600 Liabilities: Liability for MYR GmbH (“MYR”) contingent consideration $ — $ — $ 228 $ 228 $ — $ — $ 275 $ 275 Deferred compensation plan 283 — — 283 220 — — 220 Foreign currency derivative contracts — 59 — 59 — 42 — 42 Total $ 283 $ 59 $ 228 $ 570 $ 220 $ 42 $ 275 $ 538 _______________________________ (1) Publicly traded equity securities include investments in Galapagos NV (“Galapagos”) of $686 million and Arcellx, Inc. (“Arcellx”) of $373 million as of December 31, 2023, which are subject to contractual sale restrictions until August 2024 and June 2025, respectively. See Note 7. Collaborations and Other Arrangements for additional information. |
Summary of Estimated Fair Value and Carrying Value of Unsecured Notes and Liability of Future Royalty | The following table summarizes the total estimated fair value and carrying value of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values: December 31, (in millions) 2023 2022 Fair value $ 22,567 $ 21,872 Carrying value $ 23,834 $ 24,088 The following table summarizes the fair value and carrying value of the liability related to future royalties: December 31, (in millions) 2023 2022 Fair value $ 1,230 $ 1,090 Carrying value $ 1,153 $ 1,141 |
Summary of Change in Fair Value of Contingent Consideration | The following table summarizes the change in fair value of our contingent consideration liability: Year Ended December 31, (in millions) 2023 2022 Beginning balance $ 275 $ 317 Changes in valuation assumptions (1) (60) (21) Effect of foreign exchange remeasurement (2) 12 (21) Ending balance (3) $ 228 $ 275 ________________________________ (1) Included in Research and development expenses on our Consolidated Statements of Income. The changes primarily related to changes in assumptions around probability and timing of regulatory approval. (2) Included in Other income (expense), net on our Consolidated Statements of Income. (3) Included in Other long-term obligations on our Consolidated Balance Sheets as of December 31, 2023 and 2022, respectively. |
AVAILABLE-FOR-SALE DEBT SECUR_2
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Securities, Available-for-Sale [Abstract] | |
Summary of Available-for-Sale Debt Securities at Estimated Fair Value | The following table summarizes our available-for-sale debt securities: December 31, 2023 December 31, 2022 (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 427 $ — $ (1) $ 426 $ 415 $ — $ (5) $ 410 U.S. government agencies securities 127 — — 127 36 — — 35 Non-U.S. government securities 10 — — 10 34 — — 34 Certificates of deposit 45 — — 45 54 — — 54 Corporate debt securities 1,455 4 (8) 1,451 1,452 — (26) 1,427 Residential mortgage and asset-backed securities 366 1 — 367 335 — (3) 333 Total $ 2,430 $ 5 $ (10) $ 2,426 $ 2,325 $ 1 $ (34) $ 2,293 |
Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position | The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time: December 31, 2023 Less Than 12 Months 12 Months or Longer Total (in millions) Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ — $ 161 $ (1) $ 48 $ (1) $ 209 U.S. government agencies securities — 106 — 2 — 108 Non-U.S. government securities — 5 — 5 — 10 Corporate debt securities (1) 333 (7) 546 (8) 878 Residential mortgage and asset-backed securities — 123 — 24 — 147 Total $ (2) $ 727 $ (8) $ 624 $ (10) $ 1,351 December 31, 2022 Less Than 12 Months 12 Months or Longer Total (in millions) Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ (2) $ 174 $ (3) $ 206 $ (5) $ 379 U.S. government agencies securities — 21 — — — 21 Non-U.S. government securities — 31 — 3 — 34 Corporate debt securities (17) 774 (8) 439 (26) 1,213 Residential mortgage and asset-backed securities (2) 205 (1) 56 (3) 261 Total $ (22) $ 1,204 $ (12) $ 705 $ (34) $ 1,908 |
Summary of the Classification of Available-for-Sale Debt Securities | The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: December 31, (in millions) 2023 2022 Cash and cash equivalents $ 83 $ 75 Short-term marketable debt securities 1,179 973 Long-term marketable debt securities 1,163 1,245 Total $ 2,426 $ 2,293 |
Summary of Available-for-Sale Debt Securities by Contractual Maturity | The following table summarizes our available-for-sale debt securities by contractual maturity: December 31, 2023 (in millions) Amortized Cost Fair Value Within one year $ 1,267 $ 1,262 After one year through five years 1,153 1,153 After five years through ten years 9 9 After ten years 2 2 Total $ 2,430 $ 2,426 |
Summary of Equity Securities at Fair Value | The following table summarizes the classification of our equity securities on our Consolidated Balance Sheets: December 31, (in millions) 2023 2022 Equity securities measured at fair value: Cash and cash equivalents $ 4,465 $ 3,831 Prepaid and other current assets 1,086 473 Other long-term assets 656 943 Equity method investments and other equity investments without readily determinable fair values: Other long-term assets $ 340 $ 423 Total $ 6,547 $ 5,671 |
summary of Net Unrealized Gains and Losses on Equity Securities | The following table summarizes net unrealized gains and losses on equity securities still held as of the respective balance sheet dates, included in Other income (expense), net on our Consolidated Statements of Income: Year Ended December 31, (in millions) 2023 2022 2021 Net unrealized losses on equity securities still held $ 60 $ 684 $ 647 |
DERIVATIVE FINANCIAL INSTRUME_2
DERIVATIVE FINANCIAL INSTRUMENTS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Summary of Classification and Fair Value of Derivative Instruments | The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: December 31, 2023 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 6 Other current liabilities $ 38 Foreign currency exchange contracts Other long-term assets — Other long-term obligations 7 Total derivatives designated as hedges 6 45 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 15 Total derivatives not designated as hedges 1 15 Total derivatives presented gross on the Consolidated Balance Sheets $ 7 $ 59 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments $ (7) $ (7) Cash collateral received / pledged — — Net amount (legal offset) $ — $ 52 December 31, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 59 Other current liabilities $ 26 Foreign currency exchange contracts Other long-term assets 1 Other long-term obligations 9 Total derivatives designated as hedges 59 35 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 7 Total derivatives not designated as hedges 1 7 Total derivatives presented gross on the Consolidated Balance Sheets $ 60 $ 42 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments $ (36) $ (36) Cash collateral received / pledged — — Net amount (legal offset) $ 25 $ 7 |
Summary of Effect of Foreign Currency Exchange Contracts | The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements: Year Ended December 31, (in millions) 2023 2022 2021 Derivatives designated as hedges: Net (loss) gain recognized in Accumulated other comprehensive income (loss) $ (14) $ 150 $ 147 Net gain (loss) reclassified from Accumulated other comprehensive income (loss) into Product sales $ 58 $ 196 $ (67) Derivatives not designated as hedges: Net gain recognized in Other income (expense), net $ 57 $ 67 $ 21 |
ACQUISITIONS (Tables)
ACQUISITIONS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Summary of Fair Values of Assets Acquired and Liabilities Assumed | The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: (in millions) Amount Intangible assets: Finite-lived intangible asset $ 845 Acquired IPR&D 1,190 Deferred income taxes, net (513) Other assets (and liabilities), net (187) Total identifiable net assets 1,335 Goodwill 226 Total consideration $ 1,561 |
PROPERTY, PLANT AND EQUIPMENT (
PROPERTY, PLANT AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Summary of Property, Plant and Equipment | The following table summarizes our Property, plant and equipment, net by asset type: December 31, (in millions) 2023 2022 Land and land improvements $ 561 $ 562 Buildings and improvements (including leasehold improvements) 4,328 4,390 Laboratory and manufacturing equipment 1,147 1,110 Office, computer equipment and other 1,069 880 Construction in progress 661 719 Subtotal 7,766 7,661 Less: accumulated depreciation 2,449 2,186 Total $ 5,317 $ 5,475 In 2023, we wrote off $381 million of property, plant and equipment related to changes in our manufacturing strategy. The write-offs related primarily to buildings, improvements and related equipment that were determined to be fully impaired based on the difference between fair value and the carrying amount as a result of our decision to no longer utilize the facilities. The following table summarizes our Property, plant and equipment, net by geography: December 31, (in millions) 2023 2022 U.S. $ 4,691 4,501 International (1) 626 973 Total $ 5,317 $ 5,475 ________________________________ (1) All individual international locations accounted for less than 10% of the total balances. |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Summary of Goodwill | The following table summarizes the changes in the carrying amount of Goodwill: December 31, (in millions) 2023 2022 Beginning balance $ 8,314 $ 8,332 Measurement period adjustments (1) — (18) Ending balance $ 8,314 $ 8,314 ________________________________ (1) In 2022, goodwill decreased by $18 million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired. |
Summary of Indefinite-Lived Intangible Assets | The following table summarizes our Intangible assets, net: December 31, 2023 December 31, 2022 (in millions) Gross Accumulated Foreign Currency Translation Adjustment Net Carrying Amount Gross Accumulated Foreign Currency Translation Adjustment Net Carrying Amount Finite-lived assets: Intangible asset – sofosbuvir $ 10,720 $ (7,050) $ — $ 3,670 $ 10,720 $ (6,350) $ — $ 4,370 Intangible asset – axicabtagene ciloleucel 7,110 (2,314) — 4,796 7,110 (1,908) — 5,202 Intangible asset – Trodelvy (1) 11,730 (2,002) — 9,728 5,630 (973) — 4,657 Intangible asset – Hepcludex 845 (243) — 602 845 (158) — 687 Other (2) 1,414 (827) 1 588 1,489 (733) 1 758 Total finite-lived assets 31,819 (12,436) 1 19,384 25,794 (10,121) 1 15,674 Indefinite-lived assets – IPR&D (1)(3) 7,070 — — 7,070 13,220 — — 13,220 Total intangible assets $ 38,889 $ (12,436) $ 1 $ 26,454 $ 39,014 $ (10,121) $ 1 $ 28,894 _______________________________ (1) In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023. (2) In the fourth quarter of 2023, in connection with our agreement to terminate our right to receive royalties from Galapagos related to net sales of filgotinib in Europe, we wrote-off the remaining $51 million balance of our related intangible asset. See Note 7. Collaborations and Other Arrangements for additional information. (3) In the fourth quarter of 2023, due to a change in anticipated timing of FDA approval, we recognized a $50 million partial impairment of our bulevirtide IPR&D intangible asset in In-process research and development impairments on our Consolidated Statements of Income. The remaining IPR&D intangible asset balance as of December 31, 2023 was comprised of $5.9 billion for non-small cell lung cancer (“NSCLC”) indications of Trodelvy and $1.1 billion for bulveritide. |
Summary of Finite-Lived Intangible Assets | The following table summarizes our Intangible assets, net: December 31, 2023 December 31, 2022 (in millions) Gross Accumulated Foreign Currency Translation Adjustment Net Carrying Amount Gross Accumulated Foreign Currency Translation Adjustment Net Carrying Amount Finite-lived assets: Intangible asset – sofosbuvir $ 10,720 $ (7,050) $ — $ 3,670 $ 10,720 $ (6,350) $ — $ 4,370 Intangible asset – axicabtagene ciloleucel 7,110 (2,314) — 4,796 7,110 (1,908) — 5,202 Intangible asset – Trodelvy (1) 11,730 (2,002) — 9,728 5,630 (973) — 4,657 Intangible asset – Hepcludex 845 (243) — 602 845 (158) — 687 Other (2) 1,414 (827) 1 588 1,489 (733) 1 758 Total finite-lived assets 31,819 (12,436) 1 19,384 25,794 (10,121) 1 15,674 Indefinite-lived assets – IPR&D (1)(3) 7,070 — — 7,070 13,220 — — 13,220 Total intangible assets $ 38,889 $ (12,436) $ 1 $ 26,454 $ 39,014 $ (10,121) $ 1 $ 28,894 _______________________________ (1) In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023. (2) In the fourth quarter of 2023, in connection with our agreement to terminate our right to receive royalties from Galapagos related to net sales of filgotinib in Europe, we wrote-off the remaining $51 million balance of our related intangible asset. See Note 7. Collaborations and Other Arrangements for additional information. (3) In the fourth quarter of 2023, due to a change in anticipated timing of FDA approval, we recognized a $50 million partial impairment of our bulevirtide IPR&D intangible asset in In-process research and development impairments on our Consolidated Statements of Income. The remaining IPR&D intangible asset balance as of December 31, 2023 was comprised of $5.9 billion for non-small cell lung cancer (“NSCLC”) indications of Trodelvy and $1.1 billion for bulveritide. |
Summary of Estimated Future Amortization Expense of Finite-Lived Intangible Assets | The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2023: (in millions) Amount 2024 $ 2,384 2025 2,378 2026 2,370 2027 2,370 2028 2,309 Thereafter 7,571 Total $ 19,384 |
OTHER FINANCIAL INFORMATION (Ta
OTHER FINANCIAL INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Other Financial Information [Abstract] | |
Summary of Accounts Receivable, net | The following table summarizes our Accounts receivable, net: December 31, (in millions) 2023 2022 Accounts receivable $ 5,495 $ 5,464 Less: allowances for chargebacks 679 549 Less: allowances for cash discounts and other 101 83 Less: allowances for credit losses 56 55 Accounts receivable, net $ 4,660 $ 4,777 |
Summary of Inventories | The following table summarizes our Inventories: December 31, (in millions) 2023 2022 Raw materials $ 1,246 $ 1,177 Work in process 847 577 Finished goods 1,272 1,066 Total $ 3,366 $ 2,820 Reported as: Inventories $ 1,787 $ 1,507 Other long-term assets (1) 1,578 1,313 Total $ 3,366 $ 2,820 _______________________________ (1) Amounts primarily consist of raw materials. |
Summary of Other Current Liabilities | The following table summarizes the components of Other current liabilities December 31, (in millions) 2023 2022 Compensation and employee benefits $ 1,201 $ 1,018 Income taxes payable 1,208 959 Allowance for sales returns 387 422 Other 2,334 2,182 Other current liabilities $ 5,130 $ 4,580 |
Summary of Accumulated OCI by Component | The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax: (in millions) Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax Total Balance as of December 31, 2020 $ 51 $ 2 $ (113) $ (60) Net unrealized (loss) gain (38) (6) 129 85 Reclassifications to net income — — 58 58 Other comprehensive (loss) income, net (38) (6) 187 143 Balance as of December 31, 2021 $ 13 $ (4) $ 74 $ 83 Net unrealized (loss) gain $ (11) $ (30) $ 130 $ 88 Reclassifications to net income — 1 (171) (170) Other comprehensive loss, net (11) (29) (41) (81) Balance as of December 31, 2022 $ 2 $ (33) $ 33 $ 2 Net unrealized gain (loss) $ 60 $ 26 $ (12) $ 75 Reclassifications to net income — 2 (51) (49) Other comprehensive income (loss), net 60 28 (62) 26 Balance as of December 31, 2023 $ 62 $ (5) $ (29) $ 28 |
DEBT AND CREDIT FACILITIES (Tab
DEBT AND CREDIT FACILITIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Summary of Financing Arrangements | The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate December 31, 2023 December 31, 2022 Senior Unsecured September 2016 September 2023 2.50% $ — $ 749 Senior Unsecured September 2020 September 2023 0.75% — 1,498 Senior Unsecured March 2014 April 2024 3.70% 1,750 1,748 Senior Unsecured November 2014 February 2025 3.50% 1,749 1,748 Senior Unsecured September 2015 March 2026 3.65% 2,744 2,742 Senior Unsecured September 2016 March 2027 2.95% 1,248 1,247 Senior Unsecured September 2020 October 2027 1.20% 747 747 Senior Unsecured September 2020 October 2030 1.65% 994 993 Senior Unsecured September 2023 October 2033 5.25% 992 — Senior Unsecured September 2015 September 2035 4.60% 993 993 Senior Unsecured September 2016 September 2036 4.00% 743 742 Senior Unsecured September 2020 October 2040 2.60% 988 988 Senior Unsecured December 2011 December 2041 5.65% 996 996 Senior Unsecured March 2014 April 2044 4.80% 1,737 1,736 Senior Unsecured November 2014 February 2045 4.50% 1,734 1,733 Senior Unsecured September 2015 March 2046 4.75% 2,222 2,221 Senior Unsecured September 2016 March 2047 4.15% 1,729 1,728 Senior Unsecured September 2020 October 2050 2.80% 1,478 1,477 Senior Unsecured September 2023 October 2053 5.55% 988 — Total senior unsecured notes 23,834 24,088 Liability related to future royalties 1,153 1,141 Total debt, net 24,987 25,229 Less: Current portion of long-term debt and other obligations, net 1,798 2,273 Total Long-term debt, net $ 23,189 $ 22,957 |
Summary of Contractual Maturities of Financing Obligations | The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December 31, 2023: (in millions) Amount 2024 $ 1,750 2025 1,750 2026 2,750 2027 2,000 2028 — Thereafter 15,750 Total $ 24,000 |
LEASES (Tables)
LEASES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Summary of Supplemental Information Related to Operating Leases | The following table summarizes balance sheet and other information related to our operating leases: December 31, (in millions, except weighted average amounts) Classification 2023 2022 Right-of-use assets, net Other long-term assets $ 581 $ 505 Lease liabilities – current Other current liabilities $ 125 $ 111 Lease liabilities – noncurrent Other long-term obligations $ 546 $ 467 Weighted average remaining lease term 7.5 years 8.1 years Weighted average discount rate 3.22 % 2.80 % The following table summarizes other supplemental information related to our operating leases: Year Ended December 31, (in millions) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities $ 88 $ 98 Right-of-use assets obtained in exchange for lease liabilities (1) $ 214 $ 97 _______________________________ (1) These represent noncash activities and were therefore not included on our Consolidated Statements of Cash Flows. |
Summary of Operating Lease Aggregate Future Lease Payments | The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December 31, 2023: (in millions) Amount 2024 $ 143 2025 123 2026 95 2027 76 2028 70 Thereafter 257 Total undiscounted lease payments 763 Less: imputed interest 92 Total discounted lease payments $ 671 |
EMPLOYEE BENEFITS (Tables)
EMPLOYEE BENEFITS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Summary of Stock-based Compensation Expenses -Included in Consolidated Statement of Income | The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income, classified by award type and expense type: Year Ended December 31, (in millions) 2023 2022 2021 RSUs $ 666 $ 557 $ 558 PSUs 32 25 17 Stock options 30 28 29 ESPP 37 26 31 Acquisition-related expense (1) 29 8 — Stock-based compensation expense included in total costs and expenses $ 796 $ 645 $ 635 ________________________________ (1) Accelerated post-acquisition stock-based compensation expenses of $19 million and $10 million related to the 2023 XinThera and Tmunity acquisitions, respectively, and $8 million related to the 2022 MiroBio acquisition. Year Ended December 31, (in millions) 2023 2022 2021 Cost of goods sold $ 57 $ 46 $ 40 Research and development expenses 377 285 287 Selling, general and administrative expenses 361 313 308 Stock-based compensation expense included in total costs and expenses 796 645 635 Income tax effect (165) (91) (100) Stock-based compensation expense, net of tax $ 630 $ 553 $ 535 |
Summary of RSU Activity | The following tables summarize our RSU activity: RSUs (in millions, except per share amounts) Shares Weighted- Outstanding as of December 31, 2022 23.6 $ 63.62 Granted 11.5 $ 79.66 Vested (10.7) $ 63.78 Forfeited (1.6) $ 69.31 Outstanding as of December 31, 2023 22.7 $ 71.24 Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Weighted-average grant date fair value of RSUs granted $ 79.66 $ 60.36 $ 65.42 Total fair value of RSUs as of the respective vesting dates $ 849 $ 554 $ 463 |
Summary of PSU Activity | The following tables summarize our PSU activity: PSUs (in millions, except per share amounts) Shares Weighted- Outstanding as of December 31, 2022 1.0 $ 64.28 Granted 0.5 $ 81.39 Vested (0.4) $ 79.62 Forfeited (0.1) $ 59.95 Outstanding as of December 31, 2023 1.0 $ 67.48 Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Weighted-average grant date fair value of PSUs granted $ 81.39 $ 60.04 $ 71.31 Total fair value of PSUs as of the respective vesting dates $ 35 $ 14 $ 8 |
Summary of Activity Under Stock Option Plans | The following tables summarize activity and other information related to our stock options: Shares Weighted- Weighted-Average Aggregate Intrinsic Value (in millions) (1) Outstanding as of December 31, 2022 14.4 $ 67.69 Granted 2.1 $ 79.53 Exercised (1.5) $ 64.72 Forfeited (0.5) $ 66.91 Expired (0.2) $ 92.76 Outstanding as of December 31, 2023 14.3 $ 69.38 6.10 $ 177 Exercisable as of December 31, 2023 9.2 $ 70.00 4.97 $ 112 Expected to vest, net of estimated forfeitures as of December 31, 2023 4.8 $ 68.19 8.16 $ 61 ________________________________ (1) Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable . Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Weighted-average grant date fair value of stock options granted $ 16.11 $ 9.08 $ 10.05 Total intrinsic value of options exercised $ 25 $ 59 $ 48 |
Summary of Assumptions to Calculate the Estimated Fair Value of Awards | We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards: Year Ended December 31, 2023 2022 2021 Expected volatility 26 % 27 % 29 % Expected terms in years 5 5 5 Risk-free interest rate 4.1 % 1.9 % 0.8 % Expected dividend yield 3.5 % 4.3 % 4.4 % We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards: Year Ended December 31, 2023 2022 2021 Expected volatility 24 % 23 % 25 % Expected terms in years 0.5 0.5 0.5 Risk-free interest rate 5.1 % 1.8 % 0.1 % Expected dividend yield 3.7 % 4.5 % 4.4 % |
Summary of ESPP Activity | The following table summarizes our ESPP activity: Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Shares issued 2 2 2 Amount paid by employees for shares $ 129 $ 103 $ 111 Weighted-average grant date fair value of ESPP shares granted $ 17.31 $ 13.40 $ 14.58 Total fair value of ESPP shares as of the respective vesting dates $ 45 $ 21 $ 23 |
EARNINGS PER SHARE (Tables)
EARNINGS PER SHARE (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Summary of Earnings Per Share, Basic and Diluted | The following table shows the calculation of basic and diluted earnings per share attributable to Gilead: Year Ended December 31, (in millions, except per share amounts) 2023 2022 2021 Net income attributable to Gilead $ 5,665 $ 4,592 $ 6,225 Shares used in basic earnings per share attributable to Gilead calculation 1,248 1,255 1,256 Dilutive effect of stock options and equivalents 10 7 6 Shares used in diluted earnings per share attributable to Gilead calculation 1,258 1,262 1,262 Basic earnings per share attributable to Gilead 4.54 3.66 4.96 Diluted earnings per share attributable to Gilead 4.50 3.64 4.93 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Summary of Income Before Income Taxes | Income before income taxes consists of the following: Year Ended December 31, (in millions) 2023 2022 2021 Domestic $ 5,467 $ 4,439 $ 8,587 Foreign 1,392 1,375 (309) Income before income taxes $ 6,859 $ 5,814 $ 8,278 |
Summary of Income Tax Expense | Income tax expense consists of the following: Year Ended December 31, (in millions) 2023 2022 2021 Federal: Current $ (1,781) $ (2,539) $ (1,776) Deferred 1,126 1,502 250 (655) (1,037) (1,526) State: Current (80) (32) (228) Deferred (170) 154 (185) (250) 122 (413) Foreign: Current (381) (232) (185) Deferred 39 (101) 47 (342) (333) (138) Income tax expense $ (1,247) $ (1,248) $ (2,077) |
Summary of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes | The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows: Year Ended December 31, 2023 2022 2021 Federal statutory rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit 2.3 % (2.0) % 2.5 % Foreign earnings at different rates (0.2) % (0.6) % (0.3) % Research and other credits (4.3) % (2.7) % (1.6) % US tax on foreign earnings 1.0 % 2.7 % 1.1 % Foreign-derived intangible income deduction (2.1) % (3.8) % (1.6) % Tax examinations (4.7) % (0.2) % (0.7) % Acquired IPR&D & related charges 1.3 % 1.4 % — % Changes in valuation allowance 0.9 % 1.2 % 1.5 % Non-taxable unrealized loss on investment 0.2 % 0.7 % 1.8 % Other 2.8 % 3.8 % 1.4 % Effective tax rate 18.2 % 21.5 % 25.1 % |
Summary of Deferred Tax Assets and Liabilities | Significant components of our deferred tax assets and liabilities are as follows: December 31, (in millions) 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 417 $ 430 Stock-based compensation 94 95 Reserves and accruals not currently deductible 644 645 Excess of tax basis over book basis of intangible assets 1,041 1,067 Upfront and milestone payments 1,271 1,298 Research and other credit carryforwards 283 233 Equity investments 221 196 Liability related to future royalties 296 278 Capitalized R&D expenditures 1,623 784 Other, net 320 263 Total deferred tax assets before valuation allowance 6,210 5,289 Valuation allowance (663) (599) Total deferred tax assets 5,547 4,690 Deferred tax liabilities: Property, plant and equipment (274) (234) Excess of book basis over tax basis of intangible assets (5,481) (5,728) Other (184) (160) Total deferred tax liabilities (5,939) (6,122) Net deferred tax assets (liabilities) $ (392) $ (1,432) |
Summary of Unrecognized Tax Benefits Roll Forward | The following is a rollforward of our total gross unrecognized tax benefits: Year Ended December 31, (in millions) 2023 2022 2021 Beginning balance $ 1,959 $ 1,713 $ 1,614 Tax positions related to current year: Additions 265 129 147 Reductions — — — Tax positions related to prior years: Additions 109 225 161 Reductions (315) (31) (179) Settlements (42) (10) (28) Lapse of statute of limitations (13) (68) (2) Ending balance $ 1,962 $ 1,959 $ 1,713 |
Summary of Transition Tax | The following table summarizes the anticipated timing of payments associated with this transition tax as of December 31, 2023: (in millions) Amount 2024 $ 1,182 2025 1,252 Total $ 2,434 |
ORGANIZATION AND SUMMARY OF S_4
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 USD ($) segment country | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Summary of Significant Accounting Policies [Line Items] | |||
Number of countries in which entity operates | country | 35 | ||
Number of operating segments | segment | 1 | ||
Reclassification out of prepaid expenses and other | $ 39 | $ (134) | $ (45) |
Reclassification into income tax assets and liabilities, net | (1,768) | (364) | (361) |
Advertising expense | $ 826 | 778 | 735 |
Revision of Prior Period, Reclassification, Adjustment | |||
Summary of Significant Accounting Policies [Line Items] | |||
Reclassification out of prepaid expenses and other | 204 | 3 | |
Reclassification into income tax assets and liabilities, net | $ 204 | $ 3 |
ORGANIZATION AND SUMMARY OF S_5
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Property, Plant and Equipment, Estimated Useful Life (Details) | Dec. 31, 2023 |
Buildings and improvements | |
Organization And Summary Of Significant Accounting Policies [Line Items] | |
Estimated Useful Life (in years) | 35 years |
Laboratory and manufacturing equipment | Minimum | |
Organization And Summary Of Significant Accounting Policies [Line Items] | |
Estimated Useful Life (in years) | 4 years |
Laboratory and manufacturing equipment | Maximum | |
Organization And Summary Of Significant Accounting Policies [Line Items] | |
Estimated Useful Life (in years) | 10 years |
Office, computer equipment and other | Minimum | |
Organization And Summary Of Significant Accounting Policies [Line Items] | |
Estimated Useful Life (in years) | 3 years |
Office, computer equipment and other | Maximum | |
Organization And Summary Of Significant Accounting Policies [Line Items] | |
Estimated Useful Life (in years) | 15 years |
REVENUES - Summary of Disaggreg
REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disaggregation of Revenue [Line Items] | |||
Total revenues | $ 27,116 | $ 27,281 | $ 27,305 |
U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 19,438 | 18,884 | 19,267 |
Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 4,310 | 4,469 | 4,874 |
Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 3,368 | 3,928 | 3,164 |
Product sales | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 26,934 | 26,982 | 27,008 |
Product sales | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 19,377 | 18,716 | 19,176 |
Product sales | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 4,197 | 4,342 | 4,678 |
Product sales | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 3,361 | 3,924 | 3,154 |
Total HIV | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 18,175 | 17,194 | 16,315 |
Total HIV | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 14,848 | 13,820 | 12,828 |
Total HIV | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 2,102 | 2,219 | 2,366 |
Total HIV | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,226 | 1,155 | 1,121 |
Biktarvy | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 11,850 | 10,390 | 8,624 |
Biktarvy | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 9,692 | 8,510 | 7,049 |
Biktarvy | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,253 | 1,103 | 969 |
Biktarvy | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 905 | 777 | 606 |
Complera/Eviplera | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 129 | 200 | 258 |
Complera/Eviplera | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 47 | 74 | 102 |
Complera/Eviplera | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 70 | 113 | 142 |
Complera/Eviplera | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 12 | 13 | 14 |
Descovy | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,985 | 1,872 | 1,700 |
Descovy | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,771 | 1,631 | 1,397 |
Descovy | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 100 | 118 | 164 |
Descovy | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 114 | 123 | 139 |
Genvoya | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 2,060 | 2,404 | 2,879 |
Genvoya | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,752 | 1,983 | 2,267 |
Genvoya | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 205 | 284 | 391 |
Genvoya | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 103 | 136 | 221 |
Odefsey | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,350 | 1,469 | 1,568 |
Odefsey | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,012 | 1,058 | 1,076 |
Odefsey | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 294 | 364 | 440 |
Odefsey | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 44 | 47 | 52 |
Stribild | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 101 | 127 | 189 |
Stribild | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 72 | 88 | 132 |
Stribild | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 21 | 29 | 43 |
Stribild | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 8 | 10 | 14 |
Truvada | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 114 | 147 | 371 |
Truvada | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 82 | 113 | 314 |
Truvada | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 13 | 15 | 22 |
Truvada | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 19 | 18 | 35 |
Revenue share - Symtuza | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 529 | 530 | 531 |
Revenue share - Symtuza | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 382 | 348 | 355 |
Revenue share - Symtuza | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 133 | 168 | 165 |
Revenue share - Symtuza | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 13 | 14 | 11 |
Other HIV | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 56 | 57 | 195 |
Other HIV | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 37 | 15 | 136 |
Other HIV | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 12 | 24 | 30 |
Other HIV | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 7 | 17 | 29 |
Total Oncology | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 2,932 | 2,139 | 1,251 |
Total Oncology | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,833 | 1,494 | 912 |
Total Oncology | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 875 | 573 | 303 |
Total Oncology | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 224 | 73 | 36 |
Total Cell Therapy | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,869 | 1,459 | 871 |
Total Cell Therapy | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,055 | 968 | 542 |
Total Cell Therapy | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 658 | 430 | 293 |
Total Cell Therapy | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 156 | 60 | 36 |
Tecartus | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 370 | 299 | 176 |
Tecartus | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 245 | 221 | 136 |
Tecartus | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 110 | 75 | 40 |
Tecartus | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 15 | 3 | 0 |
Yescarta | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,498 | 1,160 | 695 |
Yescarta | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 811 | 747 | 406 |
Yescarta | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 547 | 355 | 253 |
Yescarta | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 140 | 57 | 36 |
Trodelvy | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,063 | 680 | 380 |
Trodelvy | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 777 | 525 | 370 |
Trodelvy | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 217 | 143 | 10 |
Trodelvy | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 68 | 12 | 0 |
Total Liver Disease | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 2,784 | 2,798 | 2,850 |
Total Liver Disease | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,421 | 1,440 | 1,415 |
Total Liver Disease | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 511 | 525 | 525 |
Total Liver Disease | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 852 | 833 | 910 |
Total HCV | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,767 | 1,810 | 1,881 |
Total HCV | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,002 | 1,005 | 1,018 |
Total HCV | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 378 | 413 | 421 |
Total HCV | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 386 | 392 | 442 |
Ledipasvir/Sofosbuvir | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 70 | 115 | 212 |
Ledipasvir/Sofosbuvir | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 39 | 46 | 84 |
Ledipasvir/Sofosbuvir | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 12 | 17 | 31 |
Ledipasvir/Sofosbuvir | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 19 | 51 | 97 |
Sofosbuvir/Velpatasvir | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,537 | 1,530 | 1,462 |
Sofosbuvir/Velpatasvir | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 859 | 844 | 815 |
Sofosbuvir/Velpatasvir | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 323 | 355 | 316 |
Sofosbuvir/Velpatasvir | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 355 | 331 | 331 |
Other HCV | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 160 | 166 | 207 |
Other HCV | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 104 | 115 | 119 |
Other HCV | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 43 | 40 | 74 |
Other HCV | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 12 | 10 | 14 |
Total HBV/HDV | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 1,017 | 988 | 969 |
Total HBV/HDV | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 418 | 435 | 397 |
Total HBV/HDV | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 133 | 112 | 104 |
Total HBV/HDV | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 466 | 441 | 468 |
Vemlidy | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 862 | 842 | 814 |
Vemlidy | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 410 | 429 | 384 |
Vemlidy | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 38 | 35 | 34 |
Vemlidy | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 414 | 379 | 396 |
Viread | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 83 | 91 | 111 |
Viread | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 8 | 6 | 11 |
Viread | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 22 | 23 | 28 |
Viread | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 52 | 62 | 72 |
Other HB/HDV | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 72 | 55 | 44 |
Other HB/HDV | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 0 | 0 | 2 |
Other HB/HDV | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 72 | 55 | 42 |
Other HB/HDV | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 0 | 0 | 0 |
Veklury | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 2,184 | 3,905 | 5,565 |
Veklury | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 972 | 1,575 | 3,640 |
Veklury | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 408 | 702 | 1,095 |
Veklury | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 805 | 1,628 | 830 |
Total Other | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 859 | 946 | 1,027 |
Total Other | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 304 | 388 | 381 |
Total Other | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 301 | 323 | 389 |
Total Other | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 255 | 235 | 257 |
AmBisome | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 492 | 497 | 540 |
AmBisome | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 43 | 57 | 39 |
AmBisome | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 260 | 258 | 274 |
AmBisome | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 189 | 182 | 227 |
Letairis | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 142 | 196 | 206 |
Letairis | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 142 | 196 | 206 |
Letairis | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 0 | 0 | 0 |
Letairis | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 0 | 0 | 0 |
Other | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 225 | 253 | 281 |
Other | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 118 | 135 | 136 |
Other | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 40 | 65 | 115 |
Other | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 66 | 53 | 30 |
Royalty, contract and other revenues | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 182 | 299 | 297 |
Royalty, contract and other revenues | U.S. | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 62 | 168 | 91 |
Royalty, contract and other revenues | Europe | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | 114 | 127 | 196 |
Royalty, contract and other revenues | Other International | |||
Disaggregation of Revenue [Line Items] | |||
Total revenues | $ 7 | $ 4 | $ 10 |
REVENUES - Summary of Revenues
REVENUES - Summary of Revenues from Major Customers (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Cardinal Health, Inc. | |||
Revenue, Major Customer [Line Items] | |||
Percentage of revenues | 26% | 25% | 22% |
Cencora, Inc. (formerly known as AmerisourceBergen Corporation) | |||
Revenue, Major Customer [Line Items] | |||
Percentage of revenues | 19% | 18% | 23% |
McKesson Corporation | |||
Revenue, Major Customer [Line Items] | |||
Percentage of revenues | 21% | 20% | 20% |
REVENUES - Summary of Revenue_2
REVENUES - Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |||
Revenue share with Janssen and royalties for licenses of intellectual property | $ 680 | $ 783 | $ 851 |
Changes in estimates | $ 340 | $ 582 | $ 856 |
Revenues - Summary of Contract
Revenues - Summary of Contract Balances (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Revenue from Contract with Customer [Abstract] | ||
Contract assets | $ 117 | $ 171 |
Contract liabilities | $ 109 | $ 102 |
FAIR VALUE MEASUREMENTS - Summa
FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Recorded at Fair Value (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Assets | ||
Available-for-sale debt securities | $ 2,426 | $ 2,293 |
Fair value, recurring | ||
Assets | ||
Total | 8,639 | 7,600 |
Liabilities: | ||
Total | 570 | 538 |
Fair value, recurring | MYR | ||
Liabilities: | ||
Liability for MYR GmbH (“MYR”) contingent consideration | 228 | 275 |
Fair value, recurring | Galapagos | ||
Liabilities: | ||
Equity investment, current | 686 | |
Equity investment, noncurrent | 736 | |
Fair value, recurring | Arcellx, Inc | ||
Liabilities: | ||
Equity investment, noncurrent | 373 | |
Level 1 | Fair value, recurring | ||
Assets | ||
Total | 6,633 | 5,658 |
Liabilities: | ||
Total | 283 | 220 |
Level 1 | Fair value, recurring | MYR | ||
Liabilities: | ||
Liability for MYR GmbH (“MYR”) contingent consideration | 0 | 0 |
Level 1 | Fair value, recurring | Galapagos | ||
Liabilities: | ||
Equity investment, current | 686 | |
Level 2 | Fair value, recurring | ||
Assets | ||
Total | 2,007 | 1,943 |
Liabilities: | ||
Total | 59 | 42 |
Level 2 | Fair value, recurring | MYR | ||
Liabilities: | ||
Liability for MYR GmbH (“MYR”) contingent consideration | 0 | 0 |
Level 3 | Fair value, recurring | ||
Assets | ||
Total | 0 | 0 |
Liabilities: | ||
Total | 228 | 275 |
Level 3 | Fair value, recurring | MYR | ||
Liabilities: | ||
Liability for MYR GmbH (“MYR”) contingent consideration | 228 | 275 |
U.S. treasury securities | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 426 | 410 |
U.S. treasury securities | Level 1 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 426 | 410 |
U.S. treasury securities | Level 2 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
U.S. treasury securities | Level 3 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
U.S. government agencies securities | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 127 | 35 |
U.S. government agencies securities | Level 1 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
U.S. government agencies securities | Level 2 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 127 | 35 |
U.S. government agencies securities | Level 3 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Non-U.S. government securities | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 10 | 34 |
Non-U.S. government securities | Level 1 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Non-U.S. government securities | Level 2 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 10 | 34 |
Non-U.S. government securities | Level 3 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Certificates of deposit | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 45 | 54 |
Certificates of deposit | Level 1 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Certificates of deposit | Level 2 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 45 | 54 |
Certificates of deposit | Level 3 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Corporate debt securities | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 1,451 | 1,427 |
Corporate debt securities | Level 1 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Corporate debt securities | Level 2 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 1,451 | 1,427 |
Corporate debt securities | Level 3 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Residential mortgage and asset-backed securities | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 367 | 333 |
Residential mortgage and asset-backed securities | Level 1 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Residential mortgage and asset-backed securities | Level 2 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 367 | 333 |
Residential mortgage and asset-backed securities | Level 3 | Fair value, recurring | ||
Assets | ||
Available-for-sale debt securities | 0 | 0 |
Money market funds | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 4,465 | 3,831 |
Money market funds | Level 1 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 4,465 | 3,831 |
Money market funds | Level 2 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 0 | 0 |
Money market funds | Level 3 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 0 | 0 |
Publicly traded equity securities | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 1,458 | 1,197 |
Publicly traded equity securities | Level 1 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 1,458 | 1,197 |
Publicly traded equity securities | Level 2 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 0 | 0 |
Publicly traded equity securities | Level 3 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 0 | 0 |
Deferred compensation plan | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 220 | |
Liabilities: | ||
Deferred compensation plan | 283 | 220 |
Deferred compensation plan | Level 1 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 284 | 220 |
Liabilities: | ||
Deferred compensation plan | 283 | 220 |
Deferred compensation plan | Level 2 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 0 | 0 |
Liabilities: | ||
Deferred compensation plan | 0 | 0 |
Deferred compensation plan | Level 3 | Fair value, recurring | ||
Assets | ||
Marketable equity securities | 0 | 0 |
Liabilities: | ||
Deferred compensation plan | 0 | 0 |
Foreign currency derivative contracts | Fair value, recurring | ||
Assets | ||
Foreign currency derivative contracts | 7 | 60 |
Liabilities: | ||
Foreign currency derivative contracts | 59 | 42 |
Foreign currency derivative contracts | Level 1 | Fair value, recurring | ||
Assets | ||
Foreign currency derivative contracts | 0 | 0 |
Liabilities: | ||
Foreign currency derivative contracts | 0 | 0 |
Foreign currency derivative contracts | Level 2 | Fair value, recurring | ||
Assets | ||
Foreign currency derivative contracts | 7 | 60 |
Liabilities: | ||
Foreign currency derivative contracts | 59 | 42 |
Foreign currency derivative contracts | Level 3 | Fair value, recurring | ||
Assets | ||
Foreign currency derivative contracts | 0 | 0 |
Liabilities: | ||
Foreign currency derivative contracts | $ 0 | $ 0 |
FAIR VALUE MEASUREMENTS - Addit
FAIR VALUE MEASUREMENTS - Additional Information (Details) € in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | ||||
Dec. 31, 2023 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Mar. 04, 2021 EUR (€) | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Aggregate amortization expense related to finite-lived intangible assets | $ 2,300 | $ 1,800 | $ 1,700 | |||
In-process research and development impairments | 50 | 2,700 | $ 0 | |||
Manufacturing Assets | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Write-off | $ 381 | |||||
In Process Research And Development Bulveritide | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
In-process research and development impairments | $ 50 | |||||
Fair Value, Nonrecurring | Galapagos | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Aggregate amortization expense related to finite-lived intangible assets | 51 | |||||
Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2- | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
In-process research and development impairments | $ 2,700 | $ 2,700 | ||||
Fair Value, Nonrecurring | In Process Research And Development Bulveritide | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
In-process research and development impairments | $ 50 | |||||
Maximum | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Foreign currency derivative contract maturities (in months) | 18 months | 18 months | ||||
Maximum | MYR | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Liability for MYR GmbH (“MYR”) contingent consideration | € | € 300 |
FAIR VALUE MEASUREMENTS - Estim
FAIR VALUE MEASUREMENTS - Estimated Fair Value and Carrying Value of Unsecured Notes and Liability of Future Royalty (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Level 2 | Fair value | ||
Fair Value, Assets and Liabilities | ||
Fair value | $ 22,567 | $ 21,872 |
Level 2 | Carrying value | ||
Fair Value, Assets and Liabilities | ||
Carrying value | 23,834 | 24,088 |
Level 3 | Fair value | Immunomedics, Inc. | Fair Value, Nonrecurring | ||
Fair Value, Assets and Liabilities | ||
Future royalties | 1,230 | 1,090 |
Level 3 | Carrying value | Immunomedics, Inc. | Fair Value, Nonrecurring | ||
Fair Value, Assets and Liabilities | ||
Future royalties | $ 1,153 | $ 1,141 |
FAIR VALUE MEASUREMENTS - Sum_2
FAIR VALUE MEASUREMENTS - Summary of Change in Fair Value of Contingent Consideration (Details) - MYR - Contingent Consideration - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Beginning balance | $ 275 | $ 317 |
Changes in valuation assumptions | (60) | (21) |
Effect of foreign exchange remeasurement | 12 | (21) |
Ending balance | $ 228 | $ 275 |
AVAILABLE-FOR-SALE DEBT SECUR_3
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Available-for-Sale Securities | ||
Amortized Cost | $ 2,430 | $ 2,325 |
Gross Unrealized Gains | 5 | 1 |
Gross Unrealized Losses | (10) | (34) |
Estimated Fair Value | 2,426 | 2,293 |
U.S. treasury securities | ||
Available-for-Sale Securities | ||
Amortized Cost | 427 | 415 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (1) | (5) |
Estimated Fair Value | 426 | 410 |
U.S. government agencies securities | ||
Available-for-Sale Securities | ||
Amortized Cost | 127 | 36 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 127 | 35 |
Non-U.S. government securities | ||
Available-for-Sale Securities | ||
Amortized Cost | 10 | 34 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 10 | 34 |
Certificates of deposit | ||
Available-for-Sale Securities | ||
Amortized Cost | 45 | 54 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 45 | 54 |
Corporate debt securities | ||
Available-for-Sale Securities | ||
Amortized Cost | 1,455 | 1,452 |
Gross Unrealized Gains | 4 | 0 |
Gross Unrealized Losses | (8) | (26) |
Estimated Fair Value | 1,451 | 1,427 |
Residential mortgage and asset-backed securities | ||
Available-for-Sale Securities | ||
Amortized Cost | 366 | 335 |
Gross Unrealized Gains | 1 | 0 |
Gross Unrealized Losses | 0 | (3) |
Estimated Fair Value | $ 367 | $ 333 |
AVAILABLE-FOR-SALE DEBT SECUR_4
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Gross Unrealized Losses | ||
Less Than 12 Months | $ (2) | $ (22) |
12 Months or Longer | (8) | (12) |
Total | (10) | (34) |
Estimated Fair Value | ||
Less Than 12 Months | 727 | 1,204 |
12 Months or Longer | 624 | 705 |
Total | 1,351 | 1,908 |
U.S. treasury securities | ||
Gross Unrealized Losses | ||
Less Than 12 Months | 0 | (2) |
12 Months or Longer | (1) | (3) |
Total | (1) | (5) |
Estimated Fair Value | ||
Less Than 12 Months | 161 | 174 |
12 Months or Longer | 48 | 206 |
Total | 209 | 379 |
U.S. government agencies securities | ||
Gross Unrealized Losses | ||
Less Than 12 Months | 0 | 0 |
12 Months or Longer | 0 | 0 |
Total | 0 | 0 |
Estimated Fair Value | ||
Less Than 12 Months | 106 | 21 |
12 Months or Longer | 2 | 0 |
Total | 108 | 21 |
Non-U.S. government securities | ||
Gross Unrealized Losses | ||
Less Than 12 Months | 0 | 0 |
12 Months or Longer | 0 | 0 |
Total | 0 | 0 |
Estimated Fair Value | ||
Less Than 12 Months | 5 | 31 |
12 Months or Longer | 5 | 3 |
Total | 10 | 34 |
Corporate debt securities | ||
Gross Unrealized Losses | ||
Less Than 12 Months | (1) | (17) |
12 Months or Longer | (7) | (8) |
Total | (8) | (26) |
Estimated Fair Value | ||
Less Than 12 Months | 333 | 774 |
12 Months or Longer | 546 | 439 |
Total | 878 | 1,213 |
Residential mortgage and asset-backed securities | ||
Gross Unrealized Losses | ||
Less Than 12 Months | 0 | (2) |
12 Months or Longer | 0 | (1) |
Total | 0 | (3) |
Estimated Fair Value | ||
Less Than 12 Months | 123 | 205 |
12 Months or Longer | 24 | 56 |
Total | $ 147 | $ 261 |
AVAILABLE-FOR-SALE DEBT SECUR_5
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Available-for-Sale Securities | |||
Allowance for credit losses | $ 0 | ||
Selling, general and administrative expenses | 6,090 | $ 5,673 | $ 5,246 |
Galapagos | Fair value, recurring | |||
Available-for-Sale Securities | |||
Marketable equity securities | 686 | ||
Equity investment, noncurrent | 736 | ||
Galapagos | Level 1 | Fair value, recurring | |||
Available-for-Sale Securities | |||
Marketable equity securities | 686 | ||
Arcus | Fair value, recurring | |||
Available-for-Sale Securities | |||
Marketable equity securities | $ 283 | 286 | |
Gilead Foundation | Related Party | |||
Available-for-Sale Securities | |||
Selling, general and administrative expenses | $ 85 | $ 212 |
AVAILABLE-FOR-SALE DEBT SECUR_6
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Debt Securities, Available-for-sale [Line Items] | ||
Total | $ 2,426 | $ 2,293 |
Cash and cash equivalents | ||
Debt Securities, Available-for-sale [Line Items] | ||
Total | 83 | 75 |
Short-term marketable debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Total | 1,179 | 973 |
Long-term marketable debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Total | $ 1,163 | $ 1,245 |
AVAILABLE-FOR-SALE DEBT SECUR_7
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Amortized Cost | ||
Within one year | $ 1,267 | |
After one year through five years | 1,153 | |
After five years through ten years | 9 | |
After ten years | 2 | |
Amortized Cost | 2,430 | $ 2,325 |
Fair Value | ||
Within one year | 1,262 | |
After one year through five years | 1,153 | |
After five years through ten years | 9 | |
After ten years | 2 | |
Fair Value | $ 2,426 | $ 2,293 |
AVAILABLE-FOR-SALE DEBT SECUR_8
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities at Fair Value (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Equity method investments and other equity investments without readily determinable fair values: | ||
Other long-term assets | $ 340 | $ 423 |
Equity securities measured at fair value and without readily determinable fair value and equity method investments | ||
Total | 6,547 | 5,671 |
Cash and cash equivalents | ||
Equity securities measured at fair value: | ||
Equity securities measured at fair value | 4,465 | 3,831 |
Prepaid and other current assets | ||
Equity securities measured at fair value: | ||
Equity securities measured at fair value | 1,086 | 473 |
Other long-term assets | ||
Equity securities measured at fair value: | ||
Equity securities measured at fair value | $ 656 | $ 943 |
AVAILABLE-FOR-SALE DEBT SECUR_9
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Net Unrealized Gains and Losses on Equity Securities (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Debt Securities, Available-for-Sale [Abstract] | |||
Net unrealized losses on equity securities still held | $ 60 | $ 684 | $ 647 |
DERIVATIVE FINANCIAL INSTRUME_3
DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Derivative [Line Items] | ||
Outstanding notional amounts on foreign currency exchange contracts | $ 2,500 | $ 3,000 |
Gain (loss) on discontinuance of cash flow hedges | $ 0 | $ 0 |
Maximum | ||
Derivative [Line Items] | ||
Maturity on derivative instruments (in months) | 18 months | |
Time estimate for gains (losses) to be reclassified from AOCI to product sales (in months) | 12 months |
DERIVATIVE FINANCIAL INSTRUME_4
DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Derivatives, Fair Value [Line Items] | ||
Derivative Assets | $ 7 | $ 60 |
Derivative financial instruments | (7) | (36) |
Cash collateral received / pledged | 0 | 0 |
Net amount (legal offset) | 0 | 25 |
Derivative Liabilities | 59 | 42 |
Derivative financial instruments | (7) | (36) |
Cash collateral received / pledged | 0 | 0 |
Net amount (legal offset) | $ 52 | $ 7 |
Derivative asset, statement of financial position | Other long-term assets, Prepaid and other current assets | Other long-term assets, Prepaid and other current assets |
Derivative liability, statement of financial position | Other current liabilities, Other long-term obligations | Other current liabilities, Other long-term obligations |
Designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Assets | $ 6 | $ 59 |
Derivative Liabilities | 45 | 35 |
Not designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Assets | 1 | 1 |
Derivative Liabilities | 15 | 7 |
Prepaid and other current assets | Designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Assets | 6 | 59 |
Prepaid and other current assets | Not designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Assets | 1 | 1 |
Other current liabilities | Designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Liabilities | 38 | 26 |
Other current liabilities | Not designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Liabilities | 15 | 7 |
Other long-term assets | Designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Assets | 0 | 1 |
Other long-term obligations | Designated as hedging instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Liabilities | $ 7 | $ 9 |
DERIVATIVE FINANCIAL INSTRUME_5
DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||
Net (loss) gain recognized in Accumulated other comprehensive income (loss) | $ (14) | $ 150 | $ 147 |
Net gain (loss) reclassified from Accumulated other comprehensive income (loss) into Product sales | 58 | 196 | (67) |
Net gain recognized in Other income (expense), net | $ 57 | $ 67 | $ 21 |
ACQUISITIONS - Additional Infor
ACQUISITIONS - Additional Information (Details) $ / shares in Units, € in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||
Feb. 12, 2024 USD ($) $ / shares | Feb. 22, 2023 USD ($) | Sep. 20, 2022 USD ($) | Mar. 04, 2021 USD ($) | Mar. 04, 2021 EUR (€) | Oct. 31, 2023 USD ($) | May 31, 2023 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Mar. 04, 2021 EUR (€) | |
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Acquired in-process research and development expenses | $ 1,155 | $ 944 | $ 939 | |||||||||
Decrease in goodwill | 0 | 18 | ||||||||||
Subsequent event | CymaBay Therapeutics, Inc. | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Acquisition consideration | $ 4,300 | |||||||||||
Acquisition share price (in dollars per share) | $ / shares | $ 32.50 | |||||||||||
MYR | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Acquisition consideration transferred | $ 1,600 | € 1,300 | ||||||||||
Cash paid for acquisition | 1,200 | € 1,000 | ||||||||||
Fair value of contingent liability | 341 | |||||||||||
Goodwill | 226 | |||||||||||
Goodwill expected to be deductible for tax purposes | 0 | |||||||||||
Decrease in goodwill | $ 18 | 18 | ||||||||||
MYR | Hepcludex | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Aggregate fair value of acquired IPR&D | 1,190 | |||||||||||
MYR | Hepcludex | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Finite-lived intangible asset | $ 845 | |||||||||||
Estimated useful life of finite-lived intangible asset acquired (in years) | 10 years | 10 years | ||||||||||
MYR | Hepcludex | Measurement Input, Discount Rate | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Discount rate of finite-lived intangible asset acquired (as percent) | 12% | 12% | ||||||||||
MYR | Maximum | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Liability for MYR GmbH (“MYR”) contingent consideration | € | € 300 | |||||||||||
XinThera, Inc | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Cash consideration | $ 200 | |||||||||||
Acquired in-process research and development expenses | $ 50 | 170 | ||||||||||
Maximum potential future milestone payments | $ 760 | |||||||||||
Tmunity Therapeutics | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Cash consideration | $ 300 | |||||||||||
Acquired in-process research and development expenses | 244 | |||||||||||
Tmunity Therapeutics | Tmunity And University Of Pennsylvania | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Acquired in-process research and development expenses | 25 | |||||||||||
Maximum potential future milestone payments | $ 1,000 | |||||||||||
MiroBio Ltd. | ||||||||||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||||||||||
Cash consideration | $ 414 | |||||||||||
Acquired in-process research and development expenses | $ 389 |
ACQUISITIONS - Summary of Fair
ACQUISITIONS - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Details) - MYR $ in Millions | Mar. 04, 2021 USD ($) |
Intangible assets: | |
Deferred income taxes, net | $ (513) |
Other assets (and liabilities), net | (187) |
Total identifiable net assets | 1,335 |
Goodwill | 226 |
Total consideration | 1,561 |
In Process Research and Development | |
Intangible assets: | |
Acquired IPR&D | 1,190 |
Intangible asset – Hepcludex | |
Intangible assets: | |
Finite-lived intangible asset | $ 845 |
COLLABORATIONS AND OTHER ARRA_2
COLLABORATIONS AND OTHER ARRANGEMENTS (Details) € in Millions, shares in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||
Dec. 21, 2021 USD ($) | Mar. 13, 2021 USD ($) | Jul. 13, 2020 USD ($) | May 27, 2020 | Jan. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | May 31, 2023 USD ($) | Apr. 30, 2022 USD ($) | Aug. 31, 2019 USD ($) shares | Dec. 31, 2018 USD ($) | Dec. 31, 2023 USD ($) | Sep. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2014 | Jun. 30, 2023 shares | Jan. 30, 2023 | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Nov. 18, 2021 program | Dec. 15, 2020 USD ($) | Dec. 15, 2020 EUR (€) | Oct. 23, 2020 USD ($) | Jul. 17, 2020 | Jun. 19, 2020 | Dec. 31, 2019 shares | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Acquired in-process research and development expenses | $ 1,155 | $ 944 | $ 939 | |||||||||||||||||||||||||||
Research and development expenses | 5,718 | 4,977 | 4,601 | |||||||||||||||||||||||||||
Other income (expense) | (198) | 581 | 639 | |||||||||||||||||||||||||||
Write-off of finite-lived intangible asset | 2,300 | 1,800 | 1,700 | |||||||||||||||||||||||||||
Cost of goods sold | 6,498 | 5,657 | 6,601 | |||||||||||||||||||||||||||
Selling, general and administrative expenses | 6,090 | 5,673 | 5,246 | |||||||||||||||||||||||||||
Abingworth | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Maximum potential future milestone payments | $ 84 | $ 84 | 84 | |||||||||||||||||||||||||||
Funding received | 50 | |||||||||||||||||||||||||||||
Abingworth | Maximum | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Funding received | 210 | |||||||||||||||||||||||||||||
Arcus | Subsequent event | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Additional equity investment | $ 320 | |||||||||||||||||||||||||||||
Option fee | $ 100 | |||||||||||||||||||||||||||||
Abingworth | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Milestone payment upon approval | 84 | 84 | 84 | |||||||||||||||||||||||||||
Dragonfly Therapeutics Collaboration Agreement | Dragonfly Therapeutics, Inc. | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Payments to acquire in process research and development | $ 300 | |||||||||||||||||||||||||||||
Additional payments to acquire in process research and development | $ 15 | |||||||||||||||||||||||||||||
Merck Sharp & Dohme Corp | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Percent of global and development and commercialization costs | 60% | |||||||||||||||||||||||||||||
Revenues recognized | 0 | 0 | 0 | |||||||||||||||||||||||||||
Option period to license certain inhibitors (in years) | 5 years | |||||||||||||||||||||||||||||
Merck Sharp & Dohme Corp | Oral Formulation Product | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Net product sales threshold | $ 2,000 | |||||||||||||||||||||||||||||
Percent of global product revenues | 65% | |||||||||||||||||||||||||||||
Merck Sharp & Dohme Corp | Injectable Formulation Product | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Net product sales threshold | $ 3,500 | |||||||||||||||||||||||||||||
Percent of global product revenues | 65% | |||||||||||||||||||||||||||||
Merck Sharp & Dohme Corp | Merck | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Percent of global and development and commercialization costs | 40% | |||||||||||||||||||||||||||||
Arcus stock purchase agreement | Arcus | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Ownership percentage by noncontrolling owners | 19.90% | |||||||||||||||||||||||||||||
Janssen pharmaceuticals | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Purchase price of goods less specified amount, maximum percentage | 30% | |||||||||||||||||||||||||||||
Cost of goods sold | 430 | 483 | 530 | |||||||||||||||||||||||||||
Period subject to termination (in years) | 10 years | |||||||||||||||||||||||||||||
Japan tobacco | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Royalty expense | 167 | 198 | 250 | |||||||||||||||||||||||||||
Cash paid | $ 559 | |||||||||||||||||||||||||||||
Finite-lived intangible assets acquired | $ 550 | |||||||||||||||||||||||||||||
Amortization useful life (in years) | 9 years | |||||||||||||||||||||||||||||
Everest Medicines | Licensing Agreements | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Finite-lived intangible assets acquired | $ 50 | |||||||||||||||||||||||||||||
Finite-lived intangible asset | $ 175 | |||||||||||||||||||||||||||||
Selling, general and administrative expenses | 406 | |||||||||||||||||||||||||||||
Everest Medicines | Everest Medicines | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Maximum potential future milestone payments | 175 | 175 | ||||||||||||||||||||||||||||
Upfront termination payments | 280 | |||||||||||||||||||||||||||||
Termination payments | 84 | 196 | ||||||||||||||||||||||||||||
Arcellx, Inc | Global Strategic Collaboration Agreement | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Acquired in-process research and development expenses | 313 | |||||||||||||||||||||||||||||
Payments to acquire shares | 299 | |||||||||||||||||||||||||||||
Percentage of profits earned | 50% | |||||||||||||||||||||||||||||
Maximum potential future milestone payments | 1,500 | 1,500 | 1,500 | |||||||||||||||||||||||||||
Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Percentage of profits earned | 50% | |||||||||||||||||||||||||||||
Arcus | Subsequent event | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Ownership percentage | 33% | |||||||||||||||||||||||||||||
Arcus | Arcus collaboration agreement and stock purchase agreements | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Acquired in-process research and development expenses | 625 | |||||||||||||||||||||||||||||
Opt-in term (in years) | 10 years | |||||||||||||||||||||||||||||
Number of clinical stage programs with exercise options | program | 3 | |||||||||||||||||||||||||||||
Collaboration opt-in payments | $ 725 | |||||||||||||||||||||||||||||
Arcus | Arcus collaboration agreement | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Maximum potential future milestone payments | $ 420 | |||||||||||||||||||||||||||||
Option continuation payment waived | $ 100 | |||||||||||||||||||||||||||||
Additional option fee on fourth, sixth, and eighth anniversaries | $ 100 | |||||||||||||||||||||||||||||
Collaboration agreement, up-front fee paid | $ 35 | |||||||||||||||||||||||||||||
Research and development expenses | 189 | 187 | ||||||||||||||||||||||||||||
Arcus | Arcus stock purchase agreement | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Maximum percentage of outstanding stock allowed to be purchased | 35% | |||||||||||||||||||||||||||||
Purchase period (in years) | 5 years | |||||||||||||||||||||||||||||
Restriction period (in years) | 3 years | |||||||||||||||||||||||||||||
Number of shares (in shares) | shares | 14.8 | |||||||||||||||||||||||||||||
Pionyr | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Ownership percentage | 49.90% | |||||||||||||||||||||||||||||
Other income (expense) | $ 70 | |||||||||||||||||||||||||||||
Pionyr | Pionyr merger and option agreements | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Equity investments balance | 0 | 0 | ||||||||||||||||||||||||||||
Tizona | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Ownership percentage | 49.90% | |||||||||||||||||||||||||||||
Other income (expense) | $ 41 | |||||||||||||||||||||||||||||
Tizona | Tizona merger and option agreements | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Equity investments balance | $ 0 | 0 | 0 | $ 0 | 0 | |||||||||||||||||||||||||
Galapagos | Fair Value, Nonrecurring | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Write-off of finite-lived intangible asset | $ 51 | |||||||||||||||||||||||||||||
Galapagos | Amended 2019 agreement | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Potential payment for adjustments of budgeted development costs | $ 190 | € 160 | ||||||||||||||||||||||||||||
Payment for adjustments of budgeted development costs in 2022 | $ 60 | $ 60 | $ 130 | € 50 | € 110 | |||||||||||||||||||||||||
Galapagos | Galapagos subscription agreement | ||||||||||||||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||||||||||||||
Ownership percentage | 25.80% | |||||||||||||||||||||||||||||
Shares of common stock acquired (in shares) | shares | 6.8 | 16.7 | ||||||||||||||||||||||||||||
Maximum ownership percentage | 29.90% | |||||||||||||||||||||||||||||
Standstill restricting term (in years) | 10 years | |||||||||||||||||||||||||||||
Minimum ownership percentage | 20.10% | |||||||||||||||||||||||||||||
Potential option exercise fee | $ 150 | |||||||||||||||||||||||||||||
Payment of tiered royalties, low-end percentage | 20% | |||||||||||||||||||||||||||||
Payment of tiered royalties, high-end percentage | 24% |
PROPERTY, PLANT AND EQUIPMENT -
PROPERTY, PLANT AND EQUIPMENT - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Abstract] | ||
Land and land improvements | $ 561 | $ 562 |
Buildings and improvements (including leasehold improvements) | 4,328 | 4,390 |
Laboratory and manufacturing equipment | 1,147 | 1,110 |
Office, computer equipment and other | 1,069 | 880 |
Construction in progress | 661 | 719 |
Subtotal | 7,766 | 7,661 |
Less: accumulated depreciation | 2,449 | 2,186 |
Total | $ 5,317 | $ 5,475 |
PROPERTY, PLANT AND EQUIPMENT_2
PROPERTY, PLANT AND EQUIPMENT - Book Value of Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, net | $ 5,317 | $ 5,475 |
U.S. | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, net | 4,691 | 4,501 |
International | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, net | $ 626 | $ 973 |
GOODWILL AND INTANGIBLE ASSET_2
GOODWILL AND INTANGIBLE ASSETS - Summary of Goodwill (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Goodwill [Roll Forward] | |||
Beginning balance | $ 8,332 | $ 8,314 | $ 8,332 |
Measurement period adjustments | 0 | (18) | |
Ending balance | 8,314 | 8,314 | |
Accumulated goodwill impairment losses | $ 0 | ||
MYR | |||
Goodwill [Roll Forward] | |||
Measurement period adjustments | $ (18) | $ (18) |
GOODWILL AND INTANGIBLE ASSET_3
GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||||
Gross Carrying Amount | $ 31,819 | $ 31,819 | $ 25,794 | ||
Accumulated Amortization | (12,436) | (12,436) | (10,121) | ||
Foreign Currency Translation Adjustment | 1 | 1 | 1 | ||
Total | 19,384 | 19,384 | 15,674 | ||
Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract] | |||||
Gross Carrying Amount | 7,070 | 7,070 | 13,220 | ||
Foreign Currency Translation Adjustment | 0 | 0 | 0 | ||
Net Carrying Amount | 7,070 | 7,070 | 13,220 | ||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Gross Carrying Amount | 38,889 | 38,889 | 39,014 | ||
Accumulated Amortization | (12,436) | (12,436) | (10,121) | ||
Foreign Currency Translation Adjustment | 1 | 1 | 1 | ||
Net Carrying Amount | 26,454 | 26,454 | 28,894 | ||
Write-off of finite-lived intangible asset | 2,300 | 1,800 | $ 1,700 | ||
In-process research and development impairments | 50 | 2,700 | $ 0 | ||
Fair Value, Nonrecurring | Galapagos | |||||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Write-off of finite-lived intangible asset | 51 | ||||
In Process Research And Development Trodelvy For HR+/HER2- | |||||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Indefinite-lived intangible assets, fair value | 6,100 | $ 6,100 | 6,100 | ||
In Process Research And Development Trodelvy For HR+/HER2- | Fair Value, Nonrecurring | |||||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
In-process research and development impairments | $ 2,700 | 2,700 | |||
In Process Research And Development Bulveritide | |||||
Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract] | |||||
Gross Carrying Amount | 1,100 | 1,100 | |||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
In-process research and development impairments | 50 | ||||
In Process Research And Development Bulveritide | Fair Value, Nonrecurring | |||||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
In-process research and development impairments | 50 | ||||
In Process Research And Development NSCLC | |||||
Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract] | |||||
Gross Carrying Amount | 5,900 | 5,900 | |||
Intangible asset – sofosbuvir | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Gross Carrying Amount | 10,720 | 10,720 | 10,720 | ||
Accumulated Amortization | (7,050) | (7,050) | (6,350) | ||
Foreign Currency Translation Adjustment | 0 | 0 | 0 | ||
Total | 3,670 | 3,670 | 4,370 | ||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Accumulated Amortization | (7,050) | (7,050) | (6,350) | ||
Intangible asset – axicabtagene ciloleucel | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Gross Carrying Amount | 7,110 | 7,110 | 7,110 | ||
Accumulated Amortization | (2,314) | (2,314) | (1,908) | ||
Foreign Currency Translation Adjustment | 0 | 0 | 0 | ||
Total | 4,796 | 4,796 | 5,202 | ||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Accumulated Amortization | (2,314) | (2,314) | (1,908) | ||
Intangible asset – Trodelvy | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Gross Carrying Amount | 11,730 | 11,730 | 5,630 | ||
Accumulated Amortization | (2,002) | (2,002) | (973) | ||
Foreign Currency Translation Adjustment | 0 | 0 | 0 | ||
Total | 9,728 | 9,728 | 4,657 | ||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Accumulated Amortization | (2,002) | (2,002) | (973) | ||
Intangible asset – Hepcludex | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Gross Carrying Amount | 845 | 845 | 845 | ||
Accumulated Amortization | (243) | (243) | (158) | ||
Foreign Currency Translation Adjustment | 0 | 0 | 0 | ||
Total | 602 | 602 | 687 | ||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Accumulated Amortization | (243) | (243) | (158) | ||
Other | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Gross Carrying Amount | 1,414 | 1,414 | 1,489 | ||
Accumulated Amortization | (827) | (827) | (733) | ||
Foreign Currency Translation Adjustment | 1 | 1 | 1 | ||
Total | 588 | 588 | 758 | ||
Intangible Assets, Net (Including Goodwill) [Abstract] | |||||
Accumulated Amortization | $ (827) | $ (827) | $ (733) |
GOODWILL AND INTANGIBLE ASSET_4
GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Intangible Assets [Line Items] | |||||
Decrease in goodwill | $ 0 | $ 18 | |||
Accumulated goodwill impairment losses | 0 | ||||
Aggregate amortization expense related to finite-lived intangible assets | $ 2,300 | $ 1,800 | $ 1,700 | ||
Discount rate of acquired IPR&D | 7.50% | 7.50% | 6.50% | ||
In-process research and development impairments | $ 50 | $ 2,700 | $ 0 | ||
In Process Research And Development Trodelvy For HR+/HER2- | |||||
Intangible Assets [Line Items] | |||||
Indefinite-lived intangible assets, fair value | $ 6,100 | $ 6,100 | |||
In Process Research And Development Trodelvy For HR+/HER2- | Fair Value, Nonrecurring | |||||
Intangible Assets [Line Items] | |||||
In-process research and development impairments | 2,700 | 2,700 | |||
MYR | |||||
Intangible Assets [Line Items] | |||||
Decrease in goodwill | $ 18 | $ 18 | |||
Immunomedics, Inc. | In Process Research And Development Trodelvy For HR+/HER2- | |||||
Intangible Assets [Line Items] | |||||
Aggregate fair value of acquired IPR&D | $ 8,800 | ||||
Immunomedics, Inc. | In Process Research And Development Trodelvy For HR+/HER2- | Measurement Input, Discount Rate | |||||
Intangible Assets [Line Items] | |||||
Discount rate, measurement input | 6.75% |
GOODWILL AND INTANGIBLE ASSET_5
GOODWILL AND INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2024 | $ 2,384 | |
2025 | 2,378 | |
2026 | 2,370 | |
2027 | 2,370 | |
2028 | 2,309 | |
Thereafter | 7,571 | |
Total | $ 19,384 | $ 15,674 |
OTHER FINANCIAL INFORMATION - S
OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Other Financial Information [Abstract] | ||
Accounts receivable | $ 5,495 | $ 5,464 |
Less: allowances for chargebacks | 679 | 549 |
Less: allowances for cash discounts and other | 101 | 83 |
Less: allowances for credit losses | 56 | 55 |
Accounts receivable, net | $ 4,660 | $ 4,777 |
OTHER FINANCIAL INFORMATION -_2
OTHER FINANCIAL INFORMATION - Summary of Inventories (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Other Financial Information [Abstract] | ||
Raw materials | $ 1,246 | $ 1,177 |
Work in process | 847 | 577 |
Finished goods | 1,272 | 1,066 |
Total | 3,366 | 2,820 |
Inventories | 1,787 | 1,507 |
Other long term assets | $ 1,578 | $ 1,313 |
OTHER FINANCIAL INFORMATION -_3
OTHER FINANCIAL INFORMATION - Summary of Other Current Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Other Financial Information [Abstract] | ||
Compensation and employee benefits | $ 1,201 | $ 1,018 |
Income taxes payable | 1,208 | 959 |
Allowance for sales returns | 387 | 422 |
Other | 2,334 | 2,182 |
Other current liabilities | $ 5,130 | $ 4,580 |
OTHER FINANCIAL INFORMATION -_4
OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | $ 21,209 | $ 21,064 | $ 18,221 |
Other comprehensive income (loss), net | 26 | (81) | 143 |
Ending balance | 22,749 | 21,209 | 21,064 |
Accumulated Other Comprehensive Income (Loss) | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | 2 | 83 | (60) |
Net unrealized (loss) gain | 75 | 88 | 85 |
Reclassifications to net income | (49) | (170) | 58 |
Other comprehensive income (loss), net | 26 | (81) | 143 |
Ending balance | 28 | 2 | 83 |
Foreign Currency Translation | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | 2 | 13 | 51 |
Net unrealized (loss) gain | 60 | (11) | (38) |
Reclassifications to net income | 0 | 0 | 0 |
Other comprehensive income (loss), net | 60 | (11) | (38) |
Ending balance | 62 | 2 | 13 |
Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | (33) | (4) | 2 |
Net unrealized (loss) gain | 26 | (30) | (6) |
Reclassifications to net income | 2 | 1 | 0 |
Other comprehensive income (loss), net | 28 | (29) | (6) |
Ending balance | (5) | (33) | (4) |
Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax | |||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | |||
Beginning balance | 33 | 74 | (113) |
Net unrealized (loss) gain | (12) | 130 | 129 |
Reclassifications to net income | (51) | (171) | 58 |
Other comprehensive income (loss), net | (62) | (41) | 187 |
Ending balance | $ (29) | $ 33 | $ 74 |
OTHER FINANCIAL INFORMATION - R
OTHER FINANCIAL INFORMATION - Restructuring (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring charges | $ 527 |
Other costs | 57 |
Cost of goods sold | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring charges | 479 |
Research and development expenses | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring charges | 20 |
Selling, general and administrative expenses | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring charges | 28 |
Manufacturing Assets | |
Restructuring Cost and Reserve [Line Items] | |
Write-off | 381 |
Inventory Write-downs | |
Restructuring Cost and Reserve [Line Items] | |
Write-off | $ 89 |
DEBT AND CREDIT FACILITIES - Su
DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Sep. 30, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | |||
Total debt, net | $ 24,987 | $ 25,229 | |
Less: Current portion of long-term debt and other obligations, net | 1,798 | 2,273 | |
Total Long-term debt, net | 23,189 | 22,957 | |
Senior notes | |||
Debt Instrument [Line Items] | |||
Total debt, net | $ 24,000 | ||
Senior notes | 2.50% Senior Unsecured Notes Due in September 2023 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 2.50% | ||
Total debt, net | $ 0 | 749 | |
Senior notes | 0.75% Senior Unsecured Notes Due in September 2023 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 0.75% | ||
Total debt, net | $ 0 | 1,498 | |
Senior notes | 3.70% Senior Unsecured Notes Due in April 2024 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 3.70% | ||
Total debt, net | $ 1,750 | 1,748 | |
Senior notes | 3.50% Senior Unsecured Notes Due in February 2025 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 3.50% | ||
Total debt, net | $ 1,749 | 1,748 | |
Senior notes | 3.65% Senior Unsecured Notes Due in March 2026 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 3.65% | ||
Total debt, net | $ 2,744 | 2,742 | |
Senior notes | 2.95% Senior Unsecured Notes Due in March 2027 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 2.95% | ||
Total debt, net | $ 1,248 | 1,247 | |
Senior notes | 1.20% Senior Unsecured Notes Due October 2027 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 1.20% | ||
Total debt, net | $ 747 | 747 | |
Senior notes | 1.65% Senior Unsecured Notes Due October 2030 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 1.65% | ||
Total debt, net | $ 994 | 993 | |
Senior notes | 5.25% Senior Unsecured Notes Due October 2033 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 5.25% | 5.25% | |
Total debt, net | $ 992 | 0 | |
Senior notes | 4.60% Senior Unsecured Notes Due in September 2035 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 4.60% | ||
Total debt, net | $ 993 | 993 | |
Senior notes | 4.00% Senior Unsecured Notes Due in September 2036 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 4% | ||
Total debt, net | $ 743 | 742 | |
Senior notes | 2.60% Senior Unsecured Notes Due October 2040 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 2.60% | ||
Total debt, net | $ 988 | 988 | |
Senior notes | 5.65% Senior Unsecured Notes Due in December 2041 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 5.65% | ||
Total debt, net | $ 996 | 996 | |
Senior notes | 4.80% Senior Unsecured Notes Due in April 2044 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 4.80% | ||
Total debt, net | $ 1,737 | 1,736 | |
Senior notes | 4.50% Senior Unsecured Notes Due in February 2045 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 4.50% | ||
Total debt, net | $ 1,734 | 1,733 | |
Senior notes | 4.75% Senior Unsecured Notes Due in March 2046 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 4.75% | ||
Total debt, net | $ 2,222 | 2,221 | |
Senior notes | 4.15% Senior Unsecured Notes Due in March 2047 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 4.15% | ||
Total debt, net | $ 1,729 | 1,728 | |
Senior notes | 2.80% Senior Unsecured Notes Due October 2050 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 2.80% | ||
Total debt, net | $ 1,478 | 1,477 | |
Senior notes | 5.55% Senior Unsecured Notes Due October 2053 | |||
Debt Instrument [Line Items] | |||
Interest Rate | 5.55% | 5.55% | |
Total debt, net | $ 988 | 0 | |
Senior Notes and Medium-Term Notes | |||
Debt Instrument [Line Items] | |||
Total senior unsecured notes | 23,834 | 24,088 | |
Liability related to future royalties | |||
Debt Instrument [Line Items] | |||
Total debt, net | $ 1,153 | $ 1,141 |
DEBT AND CREDIT FACILITIES - Ad
DEBT AND CREDIT FACILITIES - Additional Information (Details) $ in Millions | 1 Months Ended | 12 Months Ended | ||||
Sep. 30, 2023 USD ($) | Jun. 30, 2020 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Oct. 23, 2020 | |
Debt Instrument [Line Items] | ||||||
Repayments of debt | $ 2,250 | $ 1,500 | $ 4,750 | |||
Immunomedics, Inc. | Measurement Input, Expected Term | ||||||
Debt Instrument [Line Items] | ||||||
Liability related to future royalties, measurement Input | 16 | |||||
Senior notes | ||||||
Debt Instrument [Line Items] | ||||||
Principal amount | $ 2,000 | |||||
Repayments of debt | $ 2,250 | |||||
Redemption price, percentage | 101% | |||||
Senior notes | Minimum | ||||||
Debt Instrument [Line Items] | ||||||
Par call term (in months) | 2 months | |||||
Senior notes | Maximum | ||||||
Debt Instrument [Line Items] | ||||||
Par call term (in months) | 6 months | |||||
Senior notes | 5.25% Senior Unsecured Notes Due October 2033 | ||||||
Debt Instrument [Line Items] | ||||||
Principal amount | $ 1,000 | |||||
Interest rate, stated percentage | 5.25% | 5.25% | ||||
Redemption price, percentage | 100% | |||||
Senior notes | 5.55% Senior Unsecured Notes Due October 2053 | ||||||
Debt Instrument [Line Items] | ||||||
Principal amount | $ 1,000 | |||||
Interest rate, stated percentage | 5.55% | 5.55% | ||||
Redemption price, percentage | 100% | |||||
Line of credit | 2020 revolving credit facility | Revolving credit facility | ||||||
Debt Instrument [Line Items] | ||||||
Maximum borrowing capacity | $ 2,500 | |||||
Debt instrument, term (in years) | 5 years | |||||
Amounts outstanding under the facility | $ 0 | $ 0 |
DEBT AND CREDIT FACILITIES - _2
DEBT AND CREDIT FACILITIES - Summary of Contractual Maturities of Financing Obligations (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | ||
Total debt, net | $ 24,987 | $ 25,229 |
Senior notes | ||
Debt Instrument [Line Items] | ||
2024 | 1,750 | |
2025 | 1,750 | |
2026 | 2,750 | |
2027 | 2,000 | |
2028 | 0 | |
Thereafter | 15,750 | |
Total debt, net | $ 24,000 |
LEASES - Additional Information
LEASES - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Leases [Abstract] | |||
Lease term extension (in years) | 15 years | ||
Termination period (in years) | one year | ||
Operating lease expense | $ 165 | $ 162 | $ 156 |
LEASES - Summary of Balance She
LEASES - Summary of Balance Sheet Location and Other Information (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
Right-of-use assets, net | $ 581 | $ 505 |
Lease liabilities – current | 125 | 111 |
Lease liabilities – noncurrent | $ 546 | $ 467 |
Weighted average remaining lease term | 7 years 6 months | 8 years 1 month 6 days |
Weighted average discount rate | 3.22% | 2.80% |
Operating lease, right-of-use asset, statement of financial position, extensible enumeration | Other long-term assets | Other long-term assets |
Operating lease, current, statement of financial position, extensible enumeration | Other current liabilities | Other current liabilities |
Operating lease, noncurrent, statement of financial position, extensible enumeration | Other long-term obligations | Other long-term obligations |
LEASES - Summary of Supplementa
LEASES - Summary of Supplemental Information Related to Leases (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Leases [Abstract] | ||
Cash paid for amounts included in the measurement of lease liabilities | $ 88 | $ 98 |
Right-of-use assets obtained in exchange for lease liabilities | $ 214 | $ 97 |
LEASES - Summary of Operating L
LEASES - Summary of Operating Lease Liabilities Maturity (Details) $ in Millions | Dec. 31, 2023 USD ($) |
Leases [Abstract] | |
2024 | $ 143 |
2025 | 123 |
2026 | 95 |
2027 | 76 |
2028 | 70 |
Thereafter | 257 |
Total undiscounted lease payments | 763 |
Less: imputed interest | 92 |
Total discounted lease payments | $ 671 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Nov. 30, 2023 patent | Mar. 31, 2022 patent | Dec. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) plaintiff lawsuit | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | Apr. 30, 2020 agreement | |
Other Commitments [Line Items] | |||||||
Accrual for settlement related to bictegravir litigation | $ 525,000,000 | ||||||
Payments for legal settlements | $ 525,000,000 | ||||||
Accrued litigation | $ 0 | $ 0 | $ 0 | ||||
Number of patents challenged | patent | 2 | 4 | |||||
Number of patents | patent | 6 | ||||||
Pre-Exposure Prophylaxis | |||||||
Other Commitments [Line Items] | |||||||
Number of material transfer agreements | agreement | 3 | ||||||
Product Liability | |||||||
Other Commitments [Line Items] | |||||||
Number of claims filed | lawsuit | 1 | ||||||
Number of plaintiffs | plaintiff | 25,000 |
EMPLOYEE BENEFITS - Additional
EMPLOYEE BENEFITS - Additional Information (Details) - USD ($) shares in Millions, $ in Millions | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | May 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Matching contribution expense | $ 208 | $ 176 | $ 166 | |
Deferred compensation plan | Fair value, recurring | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Equity securities measured at fair value | 220 | |||
Deferred compensation plan | Fair value, recurring | Fair value | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Equity securities measured at fair value | 284 | $ 220 | ||
RSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Unrecognized compensation cost | $ 1,000 | |||
Period for recognition (in years) | 2 years 2 months 12 days | |||
ESPP | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares available for future grant (in shares) | 26 | |||
Purchase price of common stock (as percent) | 85% | |||
Capital shares reserved for future issuance (in shares) | 104 | |||
PSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Unrecognized compensation cost | $ 27 | |||
Period for recognition (in years) | 1 year 2 months 12 days | |||
Stock options | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expiration period (in years) | 10 years | |||
Unrecognized compensation cost | $ 46 | |||
Period for recognition (in years) | 2 years 2 months 12 days | |||
Minimum | RSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options vesting period (in years) | 3 years | |||
Minimum | PSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Payout percentage | 0% | |||
Minimum | Stock options | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options vesting period (in years) | 3 years | |||
Maximum | RSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options vesting period (in years) | 4 years | |||
Maximum | PSUs | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Payout percentage | 200% | |||
Maximum | Stock options | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options vesting period (in years) | 4 years | |||
2022 Equity Incentive Plan | Common Stock | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock authorized (in shares) | 132 | |||
Shares available for future grant (in shares) | 82 |
EMPLOYEE BENEFITS - Summary of
EMPLOYEE BENEFITS - Summary of Stock-Based Compensation (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | $ 796 | $ 645 | $ 635 |
Income tax effect | (165) | (91) | (100) |
Stock-based compensation expense, net of tax | 630 | 553 | 535 |
Acquisition-related expense | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 29 | 8 | 0 |
Acquisition-related expense | XinThera, Inc | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 19 | ||
Acquisition-related expense | Tmunity Therapeutics | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 10 | ||
Acquisition-related expense | MiroBio Ltd. | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 8 | ||
Cost of goods sold | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 57 | 46 | 40 |
Research and development expenses | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 377 | 285 | 287 |
Selling, general and administrative expenses | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 361 | 313 | 308 |
RSUs | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 666 | 557 | 558 |
PSUs | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 32 | 25 | 17 |
Stock options | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | 30 | 28 | 29 |
ESPP | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Stock-based compensation expense included in total costs and expenses | $ 37 | $ 26 | $ 31 |
EMPLOYEE BENEFITS - Summary o_2
EMPLOYEE BENEFITS - Summary of Restricted Stock (Details) - RSUs - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Shares | |||
Outstanding, beginning balance (in shares) | 23.6 | ||
Granted (in shares) | 11.5 | ||
Vested (in shares) | (10.7) | ||
Forfeited (in shares) | (1.6) | ||
Outstanding, ending balance (in shares) | 22.7 | 23.6 | |
Weighted- Average Grant Date Fair Value Per Share | |||
Outstanding, beginning balance (in dollars per share) | $ 63.62 | ||
Granted (in dollars per share) | 79.66 | $ 60.36 | $ 65.42 |
Vested (in dollars per share) | 63.78 | ||
Forfeited (in dollars per share) | 69.31 | ||
Outstanding, ending balance (in dollars per share) | $ 71.24 | $ 63.62 | |
Total fair value of RSUs as of the respective vesting dates | $ 849 | $ 554 | $ 463 |
EMPLOYEE BENEFITS - Summary o_3
EMPLOYEE BENEFITS - Summary of Performance Share Awards (Details) - PSUs - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Shares | |||
Outstanding, beginning balance (in shares) | 1 | ||
Granted (in shares) | 0.5 | ||
Vested (in shares) | (0.4) | ||
Forfeited (in shares) | (0.1) | ||
Outstanding, ending balance (in shares) | 1 | 1 | |
Weighted- Average Grant Date Fair Value Per Share | |||
Outstanding, beginning balance (in dollars per share) | $ 64.28 | ||
Granted (in dollars per share) | 81.39 | $ 60.04 | $ 71.31 |
Vested (in dollars per share) | 79.62 | ||
Forfeited (in dollars per share) | 59.95 | ||
Outstanding, ending balance (in dollars per share) | $ 67.48 | $ 64.28 | |
Total fair value of RSUs as of the respective vesting dates | $ 35 | $ 14 | $ 8 |
EMPLOYEE BENEFITS - Summary o_4
EMPLOYEE BENEFITS - Summary of Stock Options (Details) - Stock options - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] | |||
Outstanding, beginning balance (in shares) | 14.4 | ||
Granted (in shares) | 2.1 | ||
Exercised (in shares) | (1.5) | ||
Forfeited (in shares) | (0.5) | ||
Expired (in shares) | (0.2) | ||
Outstanding, beginning balance (in shares) | 14.3 | 14.4 | |
Exercisable (in shares) | 9.2 | ||
Expected to vest, net of estimated forfeitures (in shares) | 4.8 | ||
Weighted- Average Exercise Price (in dollars) | |||
Outstanding, beginning balance (in dollars per share) | $ 67.69 | ||
Granted (in dollars per share) | 79.53 | ||
Exercised (in dollars per share) | 64.72 | ||
Forfeited (in dollars per share) | 66.91 | ||
Expired (in dollars per share) | 92.76 | ||
Outstanding, ending balance (in dollars per share) | 69.38 | $ 67.69 | |
Exercisable (in dollars per share) | 70 | ||
Expected to vest, net of estimated forfeitures (in dollars per share) | $ 68.19 | ||
Weighted-Average Remaining Contractual Term (years) | |||
Outstanding | 6 years 1 month 6 days | ||
Exercisable | 4 years 11 months 19 days | ||
Expected to vest, net of estimated forfeitures | 8 years 1 month 28 days | ||
Aggregate Intrinsic Value (in millions) | |||
Outstanding | $ 177 | ||
Exercisable | 112 | ||
Expected to vest, net of estimated forfeitures | $ 61 | ||
Weighted average grant date fair value (in dollars per share) | $ 16.11 | $ 9.08 | $ 10.05 |
Intrinsic value of options exercised | $ 25 | $ 59 | $ 48 |
EMPLOYEE BENEFITS - Summary o_5
EMPLOYEE BENEFITS - Summary of Assumptions Used to Calculate the Fair Value of Awards (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected volatility | 26% | 27% | 29% |
Expected terms in years | 5 years | 5 years | 5 years |
Risk-free interest rate | 4.10% | 1.90% | 0.80% |
Expected dividend yield | 3.50% | 4.30% | 4.40% |
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected volatility | 24% | 23% | 25% |
Expected terms in years | 6 months | 6 months | 6 months |
Risk-free interest rate | 5.10% | 1.80% | 0.10% |
Expected dividend yield | 3.70% | 4.50% | 4.40% |
EMPLOYEE BENEFITS - Summary o_6
EMPLOYEE BENEFITS - Summary of ESPP Activity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Issuances under employee stock purchase plan | $ 129 | $ 103 | $ 111 |
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares issued | 2 | 2 | 2 |
Issuances under employee stock purchase plan | $ 129 | $ 103 | $ 111 |
Weighted-average grant date fair value of ESPP shares granted (in dollars per share) | $ 17.31 | $ 13.40 | $ 14.58 |
Total fair value of ESPP shares as of the respective vesting dates | $ 45 | $ 21 | $ 23 |
EARNINGS PER SHARE - Summary of
EARNINGS PER SHARE - Summary of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |||
Net income attributable to Gilead | $ 5,665 | $ 4,592 | $ 6,225 |
Shares used in basic earnings per share attributable to Gilead calculation (in shares) | 1,248 | 1,255 | 1,256 |
Dilutive effect of stock options and equivalents (in shares) | 10 | 7 | 6 |
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) | 1,258 | 1,262 | 1,262 |
Basic earnings per share attributable to Gilead (in dollars per share) | $ 4.54 | $ 3.66 | $ 4.96 |
Diluted earnings per share attributable to Gilead (in dollars per share) | $ 4.50 | $ 3.64 | $ 4.93 |
EARNINGS PER SHARE - Additional
EARNINGS PER SHARE - Additional Information (Details) - shares shares in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |||
Antidilutive securities excluded from computation of earnings per share (in shares) | 4 | 12 | 15 |
INCOME TAXES - Summary of Incom
INCOME TAXES - Summary of Income Before Income Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Domestic | $ 5,467 | $ 4,439 | $ 8,587 |
Foreign | 1,392 | 1,375 | (309) |
Income before income taxes | $ 6,859 | $ 5,814 | $ 8,278 |
INCOME TAXES - Summary of Inc_2
INCOME TAXES - Summary of Income Tax Expense (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Federal: | |||
Current | $ (1,781) | $ (2,539) | $ (1,776) |
Deferred | 1,126 | 1,502 | 250 |
Federal income tax expense (benefit), continuing operations | (655) | (1,037) | (1,526) |
State: | |||
Current | (80) | (32) | (228) |
Deferred | (170) | 154 | (185) |
State and local income tax expense (benefit), continuing operations | (250) | 122 | (413) |
Foreign: | |||
Current | (381) | (232) | (185) |
Deferred | 39 | (101) | 47 |
Foreign income tax expense (benefit), continuing operations | (342) | (333) | (138) |
Income tax expense | $ (1,247) | $ (1,248) | $ (2,077) |
INCOME TAXES - Summary of Diffe
INCOME TAXES - Summary of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |||
Federal statutory rate | 21% | 21% | 21% |
State taxes, net of federal benefit | 2.30% | (2.00%) | 2.50% |
Foreign earnings at different rates | (0.20%) | (0.60%) | (0.30%) |
Research and other credits | (4.30%) | (2.70%) | (1.60%) |
US tax on foreign earnings | 1% | 2.70% | 1.10% |
Foreign-derived intangible income deduction | (2.10%) | (3.80%) | (1.60%) |
Tax examinations | (4.70%) | (0.20%) | (0.70%) |
Acquired IPR&D & related charges | 1.30% | 1.40% | 0% |
Changes in valuation allowance | 0.90% | 1.20% | 1.50% |
Non-taxable unrealized loss on investment | 0.20% | 0.70% | 1.80% |
Other | 2.80% | 3.80% | 1.40% |
Effective tax rate | 18.20% | 21.50% | 25.10% |
INCOME TAXES - Summary of Defer
INCOME TAXES - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 417 | $ 430 |
Stock-based compensation | 94 | 95 |
Reserves and accruals not currently deductible | 644 | 645 |
Excess of tax basis over book basis of intangible assets | 1,041 | 1,067 |
Upfront and milestone payments | 1,271 | 1,298 |
Research and other credit carryforwards | 283 | 233 |
Equity investments | 221 | 196 |
Liability related to future royalties | 296 | 278 |
Capitalized R&D expenditures | 1,623 | 784 |
Other, net | 320 | 263 |
Total deferred tax assets before valuation allowance | 6,210 | 5,289 |
Valuation allowance | (663) | (599) |
Total deferred tax assets | 5,547 | 4,690 |
Deferred tax liabilities: | ||
Property, plant and equipment | (274) | (234) |
Excess of book basis over tax basis of intangible assets | (5,481) | (5,728) |
Other | (184) | (160) |
Total deferred tax liabilities | (5,939) | (6,122) |
Net deferred tax assets (liabilities) | $ (392) | $ (1,432) |
INCOME TAXES - Additional Infor
INCOME TAXES - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Loss Carryforwards [Line Items] | |||
Valuation allowance increase | $ 64 | $ 79 | |
Unrecognized tax benefits | 929 | 946 | |
Income tax penalties and interest (benefit) expense | (35) | (3) | $ 41 |
Accrued interest and income tax penalties | 180 | 215 | |
Accrued repatriation of foreign earnings | 2,434 | $ 3,500 | |
Decrease in unrecognized tax benefits | 400 | ||
Domestic tax authority | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | 388 | ||
Tax credit carryforward | 12 | ||
State and local jurisdiction | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | 2,700 | ||
Tax credit carryforward | $ 1,000 |
INCOME TAXES - Summary of Rollf
INCOME TAXES - Summary of Rollforward of Total Unrecognized Tax Liabilities (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Beginning balance | $ 1,959 | $ 1,713 | $ 1,614 |
Tax positions related to current year: | |||
Additions | 265 | 129 | 147 |
Reductions | 0 | 0 | 0 |
Tax positions related to prior years: | |||
Additions | 109 | 225 | 161 |
Reductions | (315) | (31) | (179) |
Settlements | (42) | (10) | (28) |
Lapse of statute of limitations | (13) | (68) | (2) |
Ending balance | $ 1,962 | $ 1,959 | $ 1,713 |
INCOME TAXES - Summary of Trans
INCOME TAXES - Summary of Transition Tax (Details) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Income Tax Disclosure [Abstract] | ||
2024 | $ 1,182 | |
2025 | 1,252 | |
Total | $ 2,434 | $ 3,500 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) - $ / shares | 1 Months Ended | 12 Months Ended | |||
Dec. 31, 2023 | Feb. 29, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Subsequent Event [Line Items] | |||||
Dividend per share (in dollars per share) | $ 0.75 | $ 3 | $ 2.92 | $ 2.84 | |
Subsequent event | |||||
Subsequent Event [Line Items] | |||||
Percentage of dividends decrease | 2.70% | ||||
Dividend per share (in dollars per share) | $ 0.77 |